Omnicell (OMCL) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 07, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'OMNICELL, Inc	'	'
Entity Central Index Key	'0000926326	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$690.50
Entity Common Stock, Shares Outstanding	'	36,362,249	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$104,531	$62,313
Accounts receivable, net of allowances of $490 and $722 at December 31, 2013 and December 31, 2012, respectively	58,597	55,116
Inventories	31,457	26,903
Prepaid expenses	18,883	15,392
Deferred tax assets	12,635	11,860
Other current assets	7,675	9,172
Total current assets	233,778	180,756
Property and equipment, net	35,254	34,107
Non-current net investment in sales-type leases	11,485	13,228
Goodwill	111,343	111,407
Other intangible assets	81,602	85,550
Non-current deferred tax assets	1,102	993
Other assets	17,937	15,778
Total assets	492,501	441,819
Current liabilities:	'	'
Accounts payable	16,471	18,255
Accrued compensation	19,604	11,613
Accrued liabilities	13,746	11,988
Deferred service revenue	22,626	20,449
Deferred gross profit	19,957	20,772
Total current liabilities	92,404	83,077
Non-current deferred service revenue	17,763	19,892
Non-current deferred tax liabilities	28,162	26,491
Other long-term liabilities	5,175	4,809
Total liabilities	143,504	134,269
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued	0	0
Common Stock, $0.001 par value; 100,000,000 shares authorized; 41,840,298 and 35,003,677 shares issued and outstanding, respectively, at December 31, 2013 and 39,493,469 and 33,541,493 shares issued and outstanding, respectively, at December 31 2012	41	39
Treasury stock, at cost, outstanding: 6,836,621 and 5,951,976 shares at December 31, 2013 and 2012, respectively	-110,962	-90,000
Additional paid-in capital	421,232	382,844
Retained earnings (accumulated deficit)	38,515	14,536
Accumulated other comprehensive income	171	131
Total stockholders' equity	348,997	307,550
Total liabilities and stockholders' equity	$492,501	$441,819

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$490	$722
Preferred Stock, Par or Stated Value Per Share	$0.00	'
Preferred Stock, Shares Authorized	5,000,000	'
Preferred Stock, Shares Issued	'	0
Common Stock, Par or Stated Value Per Share	$0.00	'
Common Stock, Shares Authorized	100,000,000	'
Common Stock, Shares, Issued	41,842,113	39,493,469
Common Stock, Shares, Outstanding	35,005,492	33,541,493
Treasury Stock, Shares	6,836,621	5,951,976

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product revenues	$307,189	$247,654	$185,864
Services and other revenues	73,396	66,373	59,671
Total revenues	380,585	314,027	245,535
Cost of revenues:	'	'	'
Cost of product revenues	144,997	112,369	79,567
Cost of services and other revenues	32,189	31,070	30,184
Total cost of revenues	177,186	143,439	109,751
Gross profit	203,399	170,588	135,784
Operating expenses:	'	'	'
Research and development	29,105	23,726	22,042
Selling, general and administrative	138,995	119,736	97,520
Total operating expenses	168,100	143,462	119,562
Income from operations	35,299	27,126	16,222
Interest and other income (expense), net	-270	-51	-133
Income before provision for income taxes	35,029	27,075	16,089
Provision for income taxes	11,050	10,897	5,700
Net income	$23,979	$16,178	$10,389
Net income per share:	'	'	'
Net income per share-basic	$0.69	$0.49	$0.31
Net income per share - diluted	$0.67	$0.47	$0.30
Weighted average shares outstanding:	'	'	'
Basic (in shares)	34,736	33,307	33,123
Diluted (in shares)	35,777	34,213	34,103

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income	$23,979	$16,178	$10,389
Other comprehensive income:	'	'	'
Unrealized holding (losses) gains arising during the period	0	-1	1
Changes in fair value of foreign currency forward hedges	-65	65	0
Foreign currency translation adjustment	105	66	0
Other comprehensive income	40	130	1
Comprehensive income	$24,019	$16,308	$10,390

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, except Share data, unless otherwise specified
Stockholders' Equity Attributable to Parent at Dec. 31, 2010	$265,214	$37	($65,064)	$342,272	($12,031)	$0
Treasury Stock, Shares at Dec. 31, 2010	'	'	-4,121,123	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	'	'	'	'	10,389	'
Net Income (Loss) Attributable to Parent	10,389	'	'	'	'	'
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'	'	1
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	1	'	'	'	'	'
Stock Repurchased and Retired During Period, Value	-12,573	'	-12,573	'	'	'
Stock Repurchased and Retired During Period, Shares	'	'	-889,511	'	'	'
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	'	'	'	9,499	'	'
Share-based compensation expense	9,499	'	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	2,737	1	'	2,736	'	'
Common stock issued under stock option and stock award plan, net of employees' taxes paid related to restricted stock units	'	641,074	'	'	'	'
Treasury Stock, Shares, Retired	'	'	-43,174	'	'	'
Stock Issued During Period, Value, Employee Stock Purchase Plan	4,050	'	'	4,050	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	445,965	'	'	'	'
Increase to additional paid in capital from share-based compensation	2,900	'	'	3,597	'	'
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	3,597	'	'	'	'	'
Common Stock, Shares, Issued	'	38,235,745	'	'	'	'
Stockholders' Equity Attributable to Parent at Dec. 31, 2011	282,914	38	-77,637	362,154	-1,642	1
Treasury Stock, Shares at Dec. 31, 2011	'	'	-5,053,808	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	'	'	'	'	16,178	'
Net Income (Loss) Attributable to Parent	16,178	'	'	'	'	'
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'	'	130
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	130	'	'	'	'	'
Stock Repurchased and Retired During Period, Value	-12,363	'	-12,363	'	'	'
Stock Repurchased and Retired During Period, Shares	'	'	-898,168	'	'	'
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	'	'	'	9,214	'	'
Share-based compensation expense	9,214	'	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	4,548	1	'	4,547	'	'
Common stock issued under stock option and stock award plan, net of employees' taxes paid related to restricted stock units	'	879,875	'	'	'	'
Stock Issued During Period, Value, Employee Stock Purchase Plan	4,402	'	'	4,402	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	377,849	'	'	'	'
Increase to additional paid in capital from share-based compensation	2,600	'	'	2,527	'	'
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	2,527	'	'	'	'	'
Common Stock, Shares, Issued	39,493,469	39,493,469	'	'	'	'
Stockholders' Equity Attributable to Parent at Dec. 31, 2012	307,550	39	-90,000	382,844	14,536	131
Common Stock, Shares, Outstanding at Dec. 31, 2012	33,541,493	'	'	'	'	'
Treasury Stock, Shares at Dec. 31, 2012	-5,951,976	'	-5,951,976	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net Income (Loss) Attributable to Parent	23,979	'	'	'	'	'
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'	'	40
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	40	'	'	'	'	'
Stock Repurchased and Retired During Period, Value	-20,962	'	20,962	'	'	'
Stock Repurchased and Retired During Period, Shares	'	'	-884,645	'	'	'
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	'	'	'	11,151	'	'
Share-based compensation expense	11,151	'	'	'	'	'
Stock Issued During Period, Value, Stock Options Exercised	18,884	2	'	18,882	'	'
Common stock issued under stock option and stock award plan, net of employees' taxes paid related to restricted stock units	'	1,897,931	'	'	'	'
Stock Issued During Period, Value, Employee Stock Purchase Plan	5,779	'	'	5,779	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	450,713	'	'	'	'
Increase to additional paid in capital from share-based compensation	2,400	'	'	2,576	'	'
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	2,576	'	'	'	'	'
Common Stock, Shares, Issued	41,842,113	41,842,113	'	'	'	'
Stockholders' Equity Attributable to Parent at Dec. 31, 2013	$348,997	$41	($110,962)	$421,232	$38,515	$171
Common Stock, Shares, Outstanding at Dec. 31, 2013	35,005,492	'	'	'	'	'
Treasury Stock, Shares at Dec. 31, 2013	-6,836,621	'	-6,836,621	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income	$23,979	$16,178	$10,389
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	18,365	13,325	7,983
Loss on disposal of fixed assets	345	66	0
Gain on legal settlement	1,759	0	0
Provision for (recovery of) receivable allowance	110	582	-155
Gain on sale of note receivable	0	0	-473
Share-based compensation expense	11,151	9,214	9,499
Income tax benefits from employee stock plans	2,576	2,527	3,597
Excess tax benefits from employee stock plans	-3,673	-3,182	-3,946
Provision for excess and obsolete inventories	856	394	1,112
Foreign currency remeasurement loss	0	0	210
Deferred Income Taxes and Tax Credits	787	2,718	589
Changes in operating assets and liabilities:	'	'	'
Accounts receivable, net	-3,609	-9,311	5,863
Inventories	-5,410	2,536	-9,434
Prepaid Expenses	-3,491	-4,897	1,464
Other current assets	1,566	-1,114	-594
Net investment in sales-type leases	1,723	-4,154	1,036
Other assets	630	-3,831	339
Accounts payable	-1,784	1,751	-2,242
Accrued compensation	7,991	4,285	-403
Increase (Decrease) in Accrued Liabilities	1,758	674	-342
Deferred Gross Profit	-815	6,562	2,491
Deferred service revenue	82	2,914	3,596
Increase in Other Noncurrent Liabilities	367	2,247	664
Net Cash Provided by Operating Activities, Continuing Operations	55,263	39,484	31,243
Cash flows from investing activities:	'	'	'
Purchases of short-term investments	0	0	-8,097
Maturities of short-term investments	0	8,122	8,143
Acquisition of intangible assets and intellectual property	-356	-373	-235
Software development for external use	-7,761	-5,028	-4,192
Purchases of property and equipment	-12,335	-15,120	-8,685
Business acquisition, net of cash acquired	0	-156,312	0
Net cash used in investing activities	-20,452	-168,711	-13,066
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock under employee stock purchase and stock option plans	24,663	8,949	6,787
Stock repurchases	-20,962	-12,363	-12,573
Excess tax benefits from employee stock plans	3,673	3,182	3,946
Net cash provided from (used in) financing activities	7,374	-232	-1,840
Effect of exchange rate changes on cash and cash equivalents	33	10	-210
Net (decrease) increase in cash and cash equivalents	42,218	-129,449	16,127
Cash and cash equivalents at beginning of period	62,313	191,762	175,635
Cash and cash equivalents at end of period	104,531	62,313	191,762
Supplemental disclosure of cash flow information:	'	'	'
Cash paid for interest	122	28	62
Cash paid for taxes	7,062	6,676	253
Purchases of property and equipment recorded in accounts payable and/or accrued liabilities	196	0	0
Satisfaction of acquired legal contingency with indemnification asset	$0	$0	($1,200)

Business_Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2013
Business Acquisition [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Business Acquisition
	MTS Medication Technologies, Inc.
	On May 21, 2012, we completed our acquisition of MedPak Holdings, Inc. ("MedPak") pursuant to an Agreement and Plan of Merger (the "Merger Agreement") under which Mercury Acquisition Corp, a newly formed Omnicell subsidiary, was merged with and into MedPak, with MedPak surviving the merger as a wholly-owned subsidiary of Omnicell. MedPak is the parent company of MTS Medication Technologies, Inc. ("MTS").
	The MTS acquisition primarily was to align Omnicell with the long term trends of the healthcare market to manage the health of patients across the continuum of care. We can now better serve both the acute care and non-acute care markets. Omnicell and MTS bring capabilities to each other that strengthen the product lines and expand the medication management coverage of both companies.
	We accounted for the acquisition in accordance with the provisions of FASB ASC Topic 805, Business Combinations. Under the acquisition method, the estimated fair value of the consideration transferred to purchase the acquired company is allocated to the assets acquired and the liabilities assumed based on their fair values. We have made significant estimates and assumptions in determining the allocation of the acquisition consideration.
	Pursuant to the terms of the Merger Agreement, we paid approximately $158.3 million in cash after adjustments provided for in the Merger Agreement, of which approximately $13.5 million was placed in an escrow fund, to be distributed to MedPak's stockholders (subject to claims that we may make against the escrow fund for indemnification and other claims following the closing). The revised acquisition consideration of $158.3 million is comprised entirely of cash at closing. In October 2012, a portion of the escrow fund set aside for the working capital adjustment was disbursed, with Omnicell receiving $0.3 million and MedPak's former stockholders receiving the remainder. In November of 2013, the remainder of the escrow fund was disbursed to the former MedPak stockholders.
	During the first quarter of 2013, we reduced goodwill by $0.1 million due to an adjustment in stockholder's equity.
	The total acquisition price was approximately $158.3 million and was allocated as follows (in thousands):
		Fair value acquired
	Cash including restricted cash	$	2,000
	Accounts receivable	7,403
	Inventory	11,726
	Deferred tax assets and other current assets	2,894
	Total current assets	24,023
	Property and equipment	9,807
	Intangible assets	83,900
	Goodwill	82,800
	Other non-current assets	308
	Total assets	200,838
	Current liabilities	(7,917		)
	Non-current deferred tax liabilities	(33,386		)
	Other non-current liabilities	(1,223		)
	Net assets acquired	$	158,312
	Cash consideration, fair value	$	158,312
	Identifiable intangible assets. Acquired technology relates to MTS’ products across all of its product lines that have reached technological feasibility, primarily the OnDemand technology. Trade name is primarily related to the MTS and OnDemand brand names. Customer relationships represent existing contracted relationships with pharmacies, institutional care facilities and others. Acquired technology, customer relationships, and trade names will be amortized on a straight-line basis over their estimated useful lives, which range from 12 to 30 years.
	The estimated fair values of the acquired technology, trade names and customer relationships were primarily determined using either the relief-from-royalty or excess earnings methods. The interest rates utilized to discount net cash flows to their present values were determined after consideration of the overall enterprise rate of return and the relative risk and importance of the assets to the generation of future cash flows.
	For income tax purposes, the historical tax bases of the acquired assets and assumed liabilities, along with the tax attributes of the MTS companies, will carry over. Because the transaction was a cash-for-stock transaction, there is no tax basis in the newly acquired intangible assets. Accordingly, the acquisition accounting includes the establishment of net deferred tax liabilities of $33.4 million, resulting from book tax basis differences related to the intangible assets acquired, as well as to the step up in the value of fixed assets and inventory to their estimated fair values at the time of acquisition.
	Details of acquired intangibles are as follows (in thousands, except for years):
		Fair value acquired			Useful Life (years)	First year amortization expense
	Trade name	$	6,800		12	$	567
	Customer relationships	50,500			28 to 30	1,707
	Acquired technology	26,600			20	1,330
	Intangibles acquired	$	83,900			$	3,604
	Weighted average life of intangibles				25.14
	Goodwill. Approximately $82.8 million has been allocated to goodwill. Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the underlying net tangible and identifiable intangible assets on the acquisition date. In accordance with ASC Topic 350, Intangibles - Goodwill and Other, goodwill will not be amortized, but instead will be tested for impairment at least annually or more frequently if certain indicators are present. We believe the MTS acquisition enhances our offerings and diversifies our revenue mix, providing a more robust product and service solution to our current customers while expanding Omnicell’s international presence. We consider these factors as supporting the amount of goodwill recorded.
	For the year ended December 31, 2012, we incurred approximately $3.2 million in acquisition-related costs in connection with the MTS acquisition. These costs are included primarily in selling, general and administrative expenses on our Consolidated Statement of Operations.
	During the year ended December 31, 2012, the acquired MTS operations (consolidated since the May 21, 2012 acquisition date) generated revenue of approximately $47.2 million and net income of $2.9 million.

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	Organization and Summary of Significant Accounting Policies
	Description of the Company.  Omnicell, Inc. ("Omnicell," "our," "us," "we," or the "Company") was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication, supply control systems and medication adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada.
	Principles of consolidation.  The consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Use of estimates.  The preparation of financial statements in accordance with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
	Cash and cash equivalents. We classify investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. Our cash and cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities from overnight to three months. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our surplus funds. We have not experienced any credit losses from our cash investments.
	Fair value of financial instruments.  We value our financial assets and liabilities on a recurring basis using the fair value hierarchy established in Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures.
	ASC 820 describes three levels of inputs that may be used to measure fair value, as follows:
	Level 1 inputs, which include quoted prices in active markets for identical assets or liabilities;
	Level 2 inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and
	Level 3 inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
	At December 31, 2013 and December 31, 2012, our financial assets utilizing Level 1 inputs included cash equivalents. For these items, quoted market prices are readily available and fair value approximates carrying value. We do not currently have any material financial instruments utilizing Level 2 or Level 3 inputs.
	Classification of marketable securities. Marketable securities for which we have the intent and ability to hold to maturity are classified as held-to-maturity, with carrying value at amortized cost, including accrued interest. We do not hold securities for purposes of trading. However, securities held as investments for the indefinite future, pending future spending requirements are classified as available-for-sale, with carrying value at fair value and any unrealized gain or loss recorded to other comprehensive income until realized. We held $65.7 million and $38.9 million of money market mutual funds as available-for-sale cash equivalents as of December 31, 2013 and 2012, respectively.
	Revenue recognition.    We earn revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues related to consumable products are reported net of discounts provided to our customers. Our customer arrangements typically include one or more of the following deliverables:
	•	Products—Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
	•	Software—Additional software applications that enable incremental functionality of our equipment.
	•	Installation—Installation of equipment as integrated systems at customers' sites.
	•	Post-installation technical support—Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
	•	Professional services—Other customer services such as training and consulting.
	We recognize revenue when the earnings process is complete, based upon our evaluation of whether the following four criteria have been met:
	•	Persuasive evidence of an arrangement exists. We use signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, we use a signed services agreement and a statement of work to evidence an arrangement.
	•	Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that we have delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, we recognize revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install our equipment at end user customer facility, we recognize revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met since we do not allow for rights of return or refund. For new distributors, where we have not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install our equipment at the end user facility. For the sale of consumable blister cards, we recognize revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from our facilities. Assuming all other revenue criteria are met, we recognize revenue for support services ratably over the related support services contract period. We recognize revenue on training and professional services as they are performed.
	•	Fee is fixed or determinable. We assess whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. We have established a history of collecting under the original contract without providing concessions on payments, products or services.
	•	Collection is probable. We assess the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in our judgment, collection of a fee is not probable, we defer the revenue until the uncertainty is removed, which generally means revenue is recognized upon our receipt of cash payment assuming all other revenue criteria are met. Our historical experience has been that collection from our customers is generally probable.
	In arrangements with multiple deliverables, assuming all other revenue criteria are met, we recognize revenue for individual delivered items if they have value to the customer on a standalone basis.We allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires us to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, we use vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. We consider VSOE to exist when approximately 80% or more of our standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). We have established VSOE of the selling price for our post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, our offerings and market strategy differ from those of our competitors, such that we cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, we use our best estimates of selling prices ("BESP"). We determine BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. We regularly review and update our VSOE and BESP information.
	The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement.
	We also use the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered.
	A portion of our sales are made through multi-year lease agreements. Under sales-type leases, we recognize revenue for our hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once our installation obligations have been met. We optimize cash flows by selling a majority of our non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold. Some of our sales-type leases, mostly those relating to U.S. government hospitals, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method.
	Accounts receivable and notes receivable (net investment in sales type leases). We actively manage our accounts receivable to minimize credit risk. We typically sell to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. We continually monitor and evaluate the collectability of our trade receivables based on a combination of factors. We record specific allowances for doubtful accounts when we become aware of a specific customer's impaired ability to meet its financial obligation to us, such as in the case of bankruptcy filings or deterioration of financial position.
	Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when we make a final determination that there is no reasonable expectation of recovery. Estimates are used in determining our allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While we believe that our allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future.
	The retained in-house leases discussed above are considered financing receivables. Our credit policies and evaluation of credit risk and write-off policies are applied alike to trade receivables and the net-investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Financing receivables which are reserved are generally transferred to cash-basis accounting so that revenue is recognized only as cash is received. However, the cash basis accounts continue to accrue interest.
	Sales of accounts receivable.  We record the sale of our accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets. During the years ended 2013, 2012 and 2011, we transferred non-recourse accounts receivable totaling $41.3 million, $60.9 million and $46.9 million, respectively, which approximated fair value, to leasing companies on a non-recourse basis. At December 31, 2013, 2012 and 2011, accounts receivable included approximately $0.1 million, $0.7 million and $0.2 million, respectively, due from third-party leasing companies for transferred non-recourse accounts receivable.
	Concentration in revenues and in accounts receivable. There were no customers accounting for 10% or more of revenues for the years ended December 31, 2013, 2012 or 2011. At December 31, 2013, 2012 and 2011, no single customer accounted for more than 10% of our accounts receivable balance.
	Geographic risk. For the years ended December 31, 2013, 2012 and 2011, 11.2%, 7.5% and 2.0%, respectively, of our product revenue was from foreign countries.
	Commissions. Sales commissions generally are earned by and paid to our sales team upon order receipt, but are recognized in expense at the time of revenue recognition. Before they are recognized as expense they are recorded as prepaid commissions, which are a component of prepaid expenses.
	Dependence on suppliers. We have a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract with our supplier may be terminated by either the supplier or by us without cause and at any time upon delivery of two months' notice. Purchases from this supplier for the years ended December 31, 2013, 2012 and 2011 were approximately $29.2 million, $23.8 million and $21.1 million, respectively.
	Inventory. Inventories are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or market. Cost elements included in inventory are direct labor and materials plus applied overhead. We routinely assess on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. We write down our inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than we projected, additional inventory write-downs may be required.
	Property and equipment. Property and equipment less accumulated depreciation are stated at historical cost. Our expenditures for property and equipment are for computer equipment and software used in the administration of our business, and for leasehold improvements to our leased facilities. We also develop molds and dies used in long-term manufacturing arrangements with suppliers, and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 years
	Equipment	3 - 5 years
	We capitalize costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Software obtained for internal use has generally been enterprise-level business and finance software that we customize to meet our specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. At December 31, 2013 and December 31, 2012, we had $4.8 million and $5.4 million, respectively, of costs related to application development of enterprise-level software included in property and equipment.
	Software development costs. We capitalize software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. We establish feasibility when we complete a working model and amortize development costs over the estimated lives of the related products ranging from three to five years. During 2013 and 2012, we capitalized software development costs of $7.8 million and $5.0 million, respectively, which are included in other assets. For the years ended December 31, 2013, 2012 and 2011, we charged to cost of revenues $3.2 million, $2.3 million, and $1.6 million, respectively, for amortization of capitalized software development costs. All development costs prior to the completion of a working model are recognized as research and development expense.
	Valuation and impairment of goodwill, other intangible assets and other long lived assets. We account for goodwill and other intangible assets in accordance with ASC 350, Intangibles—Goodwill and Other ("ASC 350). For the initial recognition and measurement of Goodwill and Intangibles resulting from acquisitions, we use the guidance in ASC 805, Business Combinations.
	Under ASC 350, Intangibles - Goodwill and Other, goodwill and intangible assets with an indefinite life are not subject to amortization but are tested for impairment at least annually or more frequently if indicators of impairment exist. ASC 350 defines impairment as the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The provisions of ASC 350 require that an entity assign its recorded goodwill to each of its reporting units and test each reporting unit's goodwill for impairment. We have determined that we have two reporting units: the Acute Care and the Non-Acute Care segments.
	In accordance with ASC 350, we have the option, in any period, to first assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill, or bypass the qualitative assessment and proceed directly to performing the two-step quantitative goodwill impairment test. The first step ("step 1") involves comparing each reporting unit's estimated fair value to its carrying value, including goodwill, to identify potential impairment. If the estimated fair value of a reporting unit exceeds its carrying value, there is no indication of impairment and no further test is required. If the carrying value exceeds the estimated fair value, there is an indication of potential impairment and the second step is required to be performed to measure the amount of impairment.
	In the fourth quarter of 2013, we elected to perform step 1 to determine whether it is more likely than not that the fair values of our reporting units are less than their carrying amounts. While the ultimate responsibility rests with management, we engaged the services of an independent, third-party valuation specialist to assist in determining the fair values of our reporting units. We used a combination of a discounted cash flow model (“DCF”) which utilizes the present value of cash flows to estimate fair value (also known as the income approach) and comparisons to publicly traded companies’ market multiples (also known as the market approach).
	Under the DCF model, the future cash flows for our reporting units were projected based on management’s projections, at that time, of future revenues, operating income and other factors such as working capital and capital expenditures. We also took into account market factors and industry conditions affecting our business. We used significant judgment to estimate the amount and timing of future cash flows from our reporting units and the relative risk of achieving those cash flows. Forecasts of future operations are based, in part, on operating results and our expectations as to future market conditions. The discount rate used in our DCF model was based on a weighted-average cost of capital determined from relevant market comparisons and adjusted for specific reporting unit risks (primarily the risk of achieving projected operating cash flows). A terminal value growth rate was applied to the final year of the respective cash flows for both reporting units to arrive at an estimate of fair value under the income approach. The estimated fair values of our reporting units determined under the income approach exceeded their carrying values.
	We used the market approach to corroborate the values estimated under the income approach. Under the market approach, we estimated the fair values of our reporting units based on financial information on companies that we deemed were comparable to our business. Based on publicly available information, we calculated the comparable companies’ market multiples of earnings before interest, taxes, depreciation and amortization, and stock option expense and factored in a control premium. The estimated fair values of our reporting units determined under the market approach exceeded their carrying values.
	Finally, we compared the estimated fair values of our reporting units to our September 30, 2013 total public market capitalization and assessed implied control premiums. Based on the aforementioned, we concluded that the estimated fair value determined for both our reporting units was reasonable. In each case, the estimated fair values of our reporting units exceeded their respective carrying values and, as such, we concluded that goodwill assigned to our Acute Care and Non-Acute Care segments was not impaired. In addition, we did not note any indications of goodwill impairment as of December 31, 2013
	In 2012, we opted to perform a qualitative assessment of factors to determine if goodwill had been impaired as of December 31, 2012. For both the Acute Care and Non-Acute Care segments, we considered the following qualitative factors:
	•	Macroeconomic conditions such as general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates or other developments in equity and credit markets;
	•	Industry and market considerations such as changes in the environment in which we operate, an increased competitive environment, a decline in market-dependent multiples or metrics (consider in both absolute terms and relative to peers), a change in the market for our products or services, or a regulatory or political development;
	•	Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on earnings and cash flows;
	•	Overall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods;
	•	Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy or litigation; and
	•	Events affecting a reporting unit such as a change in the composition or carrying amount of its net assets, a more-likely-than-not expectation of selling or disposing all, or a portion, of a reporting unit, the testing for recoverability of a significant asset group within a reporting unit or recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit.
	Upon completion of our qualitative assessment conducted in the fourth quarter of 2012, management concluded that it was more likely than not the fair values of both the Acute and Non-Acute reporting units exceeded their carrying values including the respective amounts of goodwill. In addition, management did not note any other indicators of goodwill impairment as of December 31, 2012.
	We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. We review long-lived assets and certain purchased intangibles for impairment whenever events or changes in circumstances indicate that we will not be able to recover the asset's carrying amount. Recoverability of an asset is measured by comparing its carrying amount to the expected future undiscounted cash flows expected to result from the use and eventual disposition of that asset, excluding future interest costs that would be recognized as an expense when incurred. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair market value. Significant management judgment is required in:
	•	identifying a triggering event that arises from a change in circumstances;
	•	forecasting future operating results; and
	•	estimating the proceeds from the disposition of long-lived or intangible assets.
	Significant management judgment is also required for initial recognition and measurement of goodwill and other intangibles assets resulting from business combinations in accordance with ASC 805. Management must assess the extent to which identified other intangibles assets are properly includable (and with the appropriate fair value) or properly excludable, by applying the recognition criteria. This judgment affects not only the other intangible assets but the remainder calculation of goodwill. The assessment of useful life for each acquired intangible impacts future financial position and operating performance through amortization expense.
Deferred service revenue and deferred gross profit. Deferred service revenue and deferred gross profit arise when customers are billed for products and/or services in advance of revenue recognition. Our deferred gross profit, classified as a current liability, consists primarily of unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and the unearned revenue for software licenses. Our deferred service revenue, separated into current and long-term liabilities, consists of the unearned portion of service contracts for which revenue is recognized over their duration.
Valuation of share-based awards. We account for share-based compensation plans in accordance to the provisions of ASC 718, Stock Compensation. We estimate the fair value of our employee stock awards at the date of grant using certain subjective assumptions, such as expected volatility, which is based on a combination of historical and market- based implied volatility, and the expected term of the awards which is based on our historical experience of employee stock option exercises including forfeitures. Our valuation assumptions used in estimating the fair value of share-based awards may change in future periods. We recognize the fair value of awards over their vesting period or requisite service period. In addition, we calculate our pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718.
Accounting for income taxes. We record an income tax provision for the anticipated tax consequences of the reported results of operations. In accordance with GAAP, the provision for income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities, and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, we will incur a benefit or detriment on our income tax expense in the period of change. If we were to determine that all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
In accordance with ASC 740, Income Taxes, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management's expectations could have a material impact on our financial condition and operating results.
Please refer to Note 14, Income Taxes, for further information.
Shipping costs. Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense. Such shipping and handling expenses totaled $6.1 million, $4.1 million, and $2.7 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Advertising. Advertising costs are expensed as incurred and amounted to $0.5 million, $0.5 million, and $0.9 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Operating leases. We lease our buildings under operating leases accounted for in accordance with ASC 840, Leases.
Sales taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.
Foreign currency translation. We translate the assets and liabilities of our non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity.
Currency forward contracts. From time to time we enter into foreign currency forward contracts to protect our business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and our foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value in the balance sheet. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income (a component of stockholders' equity) or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. As of December 31, 2013 and 2012, we had no foreign currency forward contracts which qualify for hedge accounting.
Total comprehensive income. The largest components of total comprehensive income for the year ended December 31, 2013 and 2012 were foreign currency translation adjustments and changes in fair value of foreign currency forward hedges.
Segment information. Prior to the acquisition of MTS, we managed our business on the basis of a single operating segment, and a single reporting unit within that segment per ASC 280, Segment Reporting. Beginning with the acquisition of MTS, which was completed in May 2012, we have organized our business into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers and Non-Acute Care, which primarily includes products and services sold to customers outside of the hospital settings.
The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
Since 1992, Omnicell has provided automation and business information solutions to acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of the acute care environment in hospitals. As the acute care market evolves, we see opportunities to provide medication adherence solutions, which were added to our product line through the acquisition of MTS. A portion of our organization structure and management processes will continue to be structured to optimize sales and service of solutions to the acute care market.
Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. A portion of our organization structure and management processes will continue to be structured to optimize the product, sales, and service of solutions to the non-acute care market.
In 2012, we realigned our management reporting structure to report sales of Omnicell's dispensing systems and other related business transactions to long-term care pharmacies and facilities. Accordingly, the operations of this portion of our activities are now being reflected as a part of the Non-Acute Care segment for the year ended December 31, 2012. Non-Acute Care segment operating results were immaterial for the year ended December 31, 2011.
Effective in the second quarter of 2013, our management changed its methodology for allocating certain expenses to our reportable segments. The impact of this change in methodology in our 2012 segment operating results was immaterial.
Substantially all of our long-lived assets are located in the United States. For the years ended December 31, 2013 and 2012, all of our total revenues and gross profits were generated by both our Acute Care and Non-Acute Care segments and no one customer accounted for greater than 10% of our revenues. For the year ended December 31, 2011, all of our total revenues and gross profits were generated by the Acute Care segment and no one customer accounted for greater than 10% of our revenues.
Recently Adopted Accounting Standards
In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("AOCI"), which aims to improve the reporting of reclassifications out of AOCI. This update requires an entity to report the effect of significant reclassifications out of AOCI on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. We adopted this guidance in the first quarter of 2013, without any impact to our financial position, operating results or cash flows.
Recently Issued Accounting Standards
In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We will adopt the amendments in ASU 2013-11 in the first quarter of 2014, and do not expect the adoption to have a material impact on our financial position, operating results or cash flows.

Net_Income_Per_Share

Net Income Per Share	12 Months Ended
	Dec. 31, 2013
Net Income Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Net Income Per Share
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, the total number of shares excluded from the calculations of diluted net income per share for the years ended December 31, 2013, 2012 and 2011 were 850,133, 2,149,044 and 1,833,574 shares, respectively.
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Years Ended December 31
		2013		2012		2011
	Basic:
	Net income	$	23,979	$	16,178	$	10,389
	Weighted average shares outstanding — basic	34,736		33,307		33,123
	Net income per share — basic	$	0.69	$	0.49	$	0.31
	Diluted:
	Net income	$	23,979	$	16,178	$	10,389
	Weighted average shares outstanding — basic	34,736		33,307		33,123
	Add: Dilutive effect of employee stock plans	1,041		906		980
	Weighted average shares outstanding — diluted	35,777		34,213		34,103
	Net income per share — diluted	$	0.67	$	0.47	$	0.3

Cash_and_Cash_Equivalents_Shor

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	'
	Cash and Cash Equivalents and Fair Value of Financial Instruments
	Cash and cash equivalents consist of the following significant investment asset classes, with disclosure of amortized cost, gross unrealized gains and losses, and fair value as of December 31, 2013 and December 31, 2012 (in thousands):
		December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market funds	65,708		—		—		65,708		65,708		Available for sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
		December 31, 2012
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	23,422	$	—	$	—	$	23,422	$	23,422	N/A
	Money market funds	38,892		—		1		38,891		38,891		Available for sale
	Total cash and cash equivalents	$	62,314	$	—	$	1	$	62,313	$	62,313
	The money market fund is a daily-traded cash equivalent with a price of $1.00, making it a Level 1 asset class, and its carrying cost closely approximates fair value. As demand deposit (cash) balances vary with the timing of collections and payments, the money market fund can cover any surplus or deficit, and thus is considered Available-for-sale.
	The following table displays the financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Significant Other		Significant		Total Fair
		Markets for Identical		Observable Inputs		Unobservable		Value
		Instruments		(Level 2)		Inputs
		(Level 1)				(Level 3)
	At December 31, 2013	$	—
	Money market funds	$	65,708	$	—	$	—	$	65,708
	Total	$	65,708	$	—	$	—	$	65,708
	At December 31, 2012
	Money market funds	$	38,891	$	—	$	—	$	38,891
	Total	$	38,891	$	—	$	—	$	38,891
	Current assets and current liabilities are recorded at amortized cost, which approximates fair value due to the short-term maturities implied.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		December 31,		December 31,
		2013		2012
	Raw materials	$	10,765	$	9,994
	Work in process	534		385
	Finished goods	20,158		16,524
	Total	$	31,457	$	26,903

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		December 31,			December 31,
		2013			2012
	Equipment	$	40,180		$	32,528
	Furniture and fixtures	5,260			5,126
	Leasehold improvements	7,394			6,992
	Purchased software	20,199			19,870
	Construction in process	2,649			2,693
		75,682			67,209
	Accumulated depreciation and amortization	(40,428		)	(33,102		)
	Property and equipment, net	$	35,254		$	34,107
	Depreciation and amortization of property and equipment was approximately $10.9 million, $8.0 million, and $5.7 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Net_Investment_in_SalesType_Le

Net Investment in Sales-Type Leases	12 Months Ended
	Dec. 31, 2013
Net Investment in Sales-Type Leases Disclosure	'
Net Investment Sales-Type Leases Disclosure [Text Block]	'
	Net Investment in Sales-Type Leases
	Our sales-type leases are for terms generally ranging up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		December 31,		December 31,
		2013		2012
	Net minimum lease payments to be received	$	18,172	$	19,665
	Less unearned interest income portion	1,455		1,205
	Net investment in sales-type leases	16,717		18,460
	Less current portion(1)	5,232		5,232
	Non-current net investment in sales-type leases(2)	$	11,485	$	13,228
	(1)     A component of other current assets. This amount is net of allowance for doubtful accounts of $0.1 million as of December 31, 2013 and $0.5 million as of December 31, 2012.
	(2)     Net of allowance for doubtful accounts of $0.1 million as of December 31, 2013 and $0.1 million as of December 31, 2012.
	The minimum lease payments under sales-type leases as of December 31, 2013 were as follows (in thousands):
	2014	$5,851
	2015	4,857
	2016	3,618
	2017	2,710
	2018	1,136
	Total	$18,172
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest, as of December 31, 2013 and December 31, 2012 (in thousands):
		Allowance for Credit Losses		Recorded Investment		Recorded Investment
				in Sales-type Leases Gross		in Sales-type Leases Net
	Credit loss disclosure for December 31, 2013:
	Accounts individually evaluated for impairment	$	—	$	—	$	—
	Accounts collectively evaluated for impairment	167		16,884		16,717
	Ending balances: December 31, 2013	$	167	$	16,884	$	16,717
	Credit loss disclosure for December 31, 2012:
	Accounts individually evaluated for impairment	$	489	$	489	$	—
	Accounts collectively evaluated for impairment	118		18,578		18,460
	Ending balances: December 31, 2012	$	607	$	19,067	$	18,460
	The following table summarizes the activity for the allowance for credit losses account for the investment in sales-type leases for the year ended December 31, 2013 (in thousands):
		Year Ended
		December 31, 2013
	Allowance for credit losses, December 31, 2012	607
	Current period provision (reversal)	49
	Direct write-downs charged against the allowance	(413	)
	Recoveries of amounts previously charged off	(76	)
	Allowance for credit losses at December 31, 2013	167

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Activity in goodwill by reporting units, which are the same as our operating segments, for the year ended December 31, 2013 consists of the following (in thousands):
		Goodwill at December 31, 2012			Adjustments to Goodwill			Goodwill at December 31, 2013
	Reporting units:
	Acute Care	$	28,543		$	—		$	28,543
	Non-Acute Care	82,864			(64		)	82,800
	Total	$	111,407		$	(64	)	$	111,343
	Goodwill reflects the May 2012 acquisition of MedPak by Omnicell. MedPak is the parent company of MTS, a worldwide provider of medication adherence packaging systems. The acquired goodwill was assigned to the Non-Acute Care segment, created as a result of the MTS acquisition. During the first quarter of 2013, we reduced goodwill by approximately $0.1 million due to the adjustment to the fair value of an acquired foreign currency forward contract previously carried in a component of stockholder's equity.
	There were no indefinite-life intangibles at either December 31, 2013 or December 31, 2012. Finite-life intangible assets at these dates consist of the following (in thousands):
		31-Dec-13							December 31, 2012
		Gross					Net		Gross		Net
		Carrying		Accumulated			Carrying		Carrying	Accumulated	Carrying	Amortization
		Amount		Amortization			Amount		Amount	Amortization	Amount	Life
	Finite-lived intangibles:
	Customer relationships	54,730		5,236			49,494		54,730	3,081	51,649	5-30 years
	Acquired technology	27,580		2,598			24,982		27,580	1,128	26,452	3-20 years
	Patents	1,493		254			1,239		1,217	259	958	20 years
	Trade name	6,890		1,003			5,887		6,890	414	6,476	3-12 years
	Non-compete agreements	60		60			—		60	45	15	3 years
	Total finite-lived intangibles	90,753		9,151			81,602		90,477	4,927	85,550
	During 2013, 2012 and 2011, we capitalized third-party costs associated with internally-developed patents of $0.4 million, $0.4 million and $0.2 million, respectively.
	Amortization expense of other intangible assets totaled $4.3 million, $2.9 million and $0.7 million for the years ended December 31, 2013, 2012 and 2011, respectively. The amortization of acquired technology is included within product cost of sales; other acquired intangibles are usually amortized within selling, general and administrative expenses.
	Estimated annual expected amortization expense of the finite-lived intangible assets at December 31, 2013 was as follows (in thousands):
	2014	4,229
	2015	4,204
	2016	3,854
	2017	3,818
	2018	3,711
	Thereafter	61,786
	Total	$	81,602

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Other Assets Disclosure [Text Block]	'
	Other Assets
	Other assets consist of the following (in thousands):
		December 31,
		2013		2012
	Capitalized software development costs, net of accumulated amortization of $10,547 and $7,329 in 2013 and 2012, respectively	$	13,660	$	11,037
	Technology license	2,350		2,800
	Long-term deposits	682		694
	Other assets	1,245		1,247
	Total	$	17,937	$	15,778

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'
Accrued Liabilities [Text Block]	'
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		December 31,		December 31,
		2013		2012
	Rebates and lease buyouts	$	1,699	$	3,179
	Advance payments from customers	4,971		2,829
	Accrued Group Purchasing Organization (GPO) fees	2,324		2,278
	Technology license purchase obligation, current portion	1,500		1,750
	Taxes payable	1,664		555
	Other	1,588		1,397
	Total	$	13,746	$	11,988

Deferred_Gross_Profit

Deferred Gross Profit	12 Months Ended
	Dec. 31, 2013
Deferred Gross Profit [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Deferred Gross Profit
	Deferred gross profit consists of the following (in thousands):
		December 31,			December 31,
		2013			2012
	Sales of medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$	29,040		$	30,138
	Cost of revenues, excluding installation costs	(9,083		)	(9,366		)
	Deferred gross profit	$	19,957		$	20,772

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments	'
Commitments Disclosure [Text Block]	'
	Commitments
	At December 31, 2013, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	2014	$	5,787
	2015	5,476
	2016	5,150
	2017	4,468
	2018	4,298
	Thereafter	16,601
	Total	$	41,780
	Commitments under operating leases relate primarily to leasehold property and office equipment. Rent expense totaled $8.1 million, $5.7 million and $3.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. For 2011,we had $0.5 million of non-cancelable sublease income.
	In October 2011, we entered into a lease agreement for approximately 100,000 square feet of office space. Pursuant to the lease agreement, the landlord constructed a single, three-story building of rentable space in Mountain View, California which we now lease and which serves as our headquarters. The term of the lease agreement, which commenced in November 2012, is for a period of 10 years, with a base lease commitment of approximately $40.0 million. We have two options to extend the term of the lease agreement at market rates. Each extension is for an additional 60 month term.
	In March 2012, we entered into a lease agreement for approximately 46,000 square feet of manufacturing, distribution and office space located in Milpitas, California which commenced in October, 2012. The term of the lease agreement is for a period of 60 months, with a base lease commitment of approximately $1.8 million and a single 60 month extension option.
	In connection with the acquisition of MTS, we assumed responsibility for its 132,500 square feet of manufacturing, warehousing and office space in St. Petersburg, Florida. The remaining term of the original twelve year lease agreement, which expires in September 2016 and at the time of the MTS acquisition, had a remaining base lease commitment of approximately $3.9 million. We have two options to extend the term of the lease agreement at market rates. Each extension is for an additional 60 month term.
	In Leeds, United Kingdom, we lease an office and distribution center of approximately 16,500 square feet. The remaining term of the original ten year lease agreement is through June 8, 2021, with no extension options. The base lease commitment at the time of the MTS acquisition, converted from British Pounds at the conversion rate then in effect, was approximately $1.2 million.
	We also have smaller rented offices in Strongsville, Ohio, Nashville, Tennessee, Waukegan, Illinois, the United Arab Emirates, the People's Republic of China and the Federal Republic of Germany.
	We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. Our near-term commitments to our contract manufacturers and suppliers totaled $7.4 million as of December 31, 2013.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	Legal Proceedings
	On March 8, 2013, Bobbi Polanco (“Polanco”) filed a putative class action complaint in the United States District Court for the District of New Jersey (the "Court") against Omnicell and certain of our customers (Case No. 1:13-cv-01417-NLH-KLM) alleging breach of state security notification laws, violations of state consumer fraud laws, fraud, negligence and conspiracy relating to the theft of an Omnicell electronic device containing medication dispensing cabinet log files, including certain patient health information, and subsequent notification of this unauthorized disclosure of personal health information. Polanco is seeking an injunction against the defendants to prevent each of them from committing the acts complained of in the future and monetary damages, costs and expenses. On May 2, 2013, the Court entered an order to show cause which provided, in relevant part, that Polanco is required to show cause as to why the case should not be dismissed for lack of subject matter jurisdiction. On May 13, 2013, Polanco filed an amended complaint. On May 31, 2013, Omnicell filed a motion to dismiss the complaint on the grounds that Polanco failed to satisfy constitutional standing requirements and that she failed to state a claim against Omnicell  for violating  state data breach notification statutes, consumer fraud, common law fraud, negligence and conspiracy. Omnicell also joined in the arguments of the other defendants seeking dismissal. On July 1, 2013, Polanco filed an opposition to the motions to dismiss. On July 15, 2013, Omnicell filed its reply to the opposition from Polanco. In December 2013, the Court granted the defendants' motions to dismiss without prejudice. Polanco failed to file an appeal of the Court's decision by the January 27, 2014 deadline.
	As required under ASC 450, Contingencies, we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described above based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses.
	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2013 or December 31, 2012.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Income Taxes
	The following is a geographical breakdown of income before the provision for income taxes (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Domestic	$	34,678		$	25,794		$	16,177
	Foreign	351			1,281			(88		)
	Total income before provision for income taxes	$	35,029		$	27,075		$	16,089
	The provision for income taxes consists of the following (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	8,218		$	7,181		$	4,285
	State	1,621			1,006			896
	Foreign	447			154			(70		)
	Total current	10,286			8,341			5,111
	Deferred:
	Federal	1,287			2,169			1,116
	State	(263		)	651			(527		)
	Foreign	(260		)	(264		)	—
	Total deferred	764			2,556			589
	Total provision for income taxes	$	11,050		$	10,897		$	5,700
	The provision for income taxes differs from the amount computed by applying the statutory federal tax rate as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	U.S. federal tax provision at statutory rate	$	12,260		$	9,476		$	5,631
	State taxes	883			1,077			240
	Non-deductible expenses	297			530			481
	Acquisition costs	—			431			—
	Share-based compensation expense	407			403			443
	Research tax credits	(1,430		)	—			(755		)
	Domestic production deduction	(816		)	(601		)	(271		)
	Other	(551		)	(419		)	(69		)
	Total	$	11,050		$	10,897		$	5,700
	Significant components of our deferred tax assets (liabilities) are as follows (in thousands):
		December 31,
		2013			2012
	Deferred tax assets (liabilities):
	Tax credit carry forwards	$	3,160		$	2,990
	Inventory related items	2,947			2,900
	Deferred revenue	11,074			11,497
	Stock compensation	7,447			9,331
	Loss carry forwards	64			53
	Other, net	5			69
	Subtotal	24,697			26,840
	Less: valuation allowance	(39		)	(39		)
	Total net deferred tax assets	24,658			26,801
	Reserves and accruals	(353		)	(573		)
	Depreciation and amortization	(38,681		)	(39,840		)
	Total deferred tax liabilities	(39,034		)	(40,413		)
	Net deferred tax liabilities	$	(14,376	)	$	(13,612	)
	Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carry forwards. We recognize deferred tax assets to the extent that we believe these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. On the basis of this evaluation, as of December 31, 2013, no significant valuation allowances have been recorded in any jurisdiction.
	As of December 31, 2013, we had state net operating loss carry forwards available for state income tax purposes of approximately $2.2 million. If not utilized, these carry forwards will begin to expire in 2026. In addition, as of December 31, 2013 we had federal and California research credit carry forwards of approximately $1.5 million and $7.2 million, respectively. If not utilized the federal credit carry forwards will begin to expire in 2022, while the California credits can be carried forward indefinitely. Pursuant to the requirements of ASC 718, we do not include unrealized stock option attributes as components of our deferred tax assets. The tax effected amounts of gross unrealized net operating loss and business tax credit carry forwards excluded under ASC 718 for the year ended December 31, 2013 are approximately $2.6 million, which will result in increases to additional paid in capital if and when realized as a reduction in income taxes otherwise paid.
	In general, it is our practice and intention to reinvest the earnings of our non-U.S. subsidiaries in those operations. As of December 31, 2013, we have not made a provision for U.S. federal income and state income taxes on accumulated and current earnings of $2.8 million related to our U.K. and German subsidiaries because these earnings are intended to be indefinitely reinvested in operations outside the United States. If we expect to distribute those earnings in the form of dividends or otherwise, we would be subject to U.S. and state income taxes reported as a component of income tax expense, in the amount of $1.1 million. This amount may be reduced by any foreign tax credits available at the time of repatriation.
	We file income tax returns in the U.S. and various states and foreign jurisdictions. In the normal course of business, we are subject to examination by tax authorities, including in major jurisdictions in the United States, California, UK and Germany. In 2012, we concluded audits by the Internal Revenue Service and California Franchise Tax Board for tax years 2008 and 2009. However, all of the net operating loss and research credit carry forwards that may be used in future years are subject to adjustment, if and when utilized. As such our federal and California tax years remain open from 1996 and 1992, respectively.
	The aggregate changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2013 is as follows (in thousands):
	Balance as of December 31, 2010	$	5,431
	Decreases related to tax positions taken during the prior period	(88		)
	Increases related to tax positions taken during the current period	453
	Balance as of December 31, 2011	$	5,796
	Increases related to tax positions taken during a prior period	43
	Increases related to tax positions related to MTS	1,066
	Increases related to tax positions taken during the current period	422
	Decreases related to settlements	(33		)
Decreases related to expiration of statute of limitations	(379		)
Balance as of December 31, 2012	$	6,915
Increases related to tax positions taken during a prior period	406
Decreases related to tax positions taken during the prior period	(79		)
Increases related to tax positions taken during the current period	764
Decreases related to expiration of statute of limitations	(32		)
Balance as of December 31, 2013	$	7,974
As of December 31, 2013, the total amount of gross unrecognized tax benefits, if realized, would affect our tax expense by approximately $7.0 million. Our policy is to recognize interest and penalties related to unrecognized tax benefits in operating expenses. The total amount of interest and penalties recorded in 2013 was not significant. We do not expect any material changes to our unrecognized tax benefits over the next twelve months.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Treasury Stock
	2008 Stock Repurchase Program
	In February 2008, our Board of Directors authorized a stock repurchase program, (the "2008 Repurchase Program") for the repurchase of up to $90.0 million of our common stock. The timing, price and volume of the repurchases have been based on market conditions, relevant securities laws and other factors.
	For the year ended December 31, 2012, we repurchased 898,168 shares at an average cost of $13.76 per share, including commissions. For the year ended December 31, 2011, we repurchased 889,511 shares at an average cost of $14.13 per share, including commissions. All repurchased shares were recorded as treasury stock and were accounted for under the cost method. No repurchased shares have been retired. Additionally, for the years ended December 31, 2013, 2012 and 2011, we withheld 103,229 shares, 79,968 shares and 43,174 shares, respectively, from employees to satisfy tax withholding obligations on the vesting of restricted stock.
	From the inception of the 2008 Repurchase Program in February 2008 through December 31, 2012, we repurchased a total of 5,853,975 shares at an average cost of $15.37 per share through open market purchases. As of December 31, 2012, we have completed the 2008 Repurchase Program having repurchased $90.0 million of our common stock.
	2012 Stock Repurchase Program
	On August 1, 2012, our Board of Directors established a new stock repurchase program (the "2012 Repurchase Program") authorizing share repurchases of up to $50.0 million of our common stock, with no termination date. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan. The stock repurchase program does not obligate us to repurchase any specific number of shares, and Omnicell may terminate or suspend the repurchase program at any time
	For the year ended December 31, 2013, and from the inception of the 2012 Repurchase Program, we have repurchased a total of $21.0 million, or 884,645 shares at an average cost of $23.70 per share, including commissions. As of December 31, 2013, the maximum dollar value of shares that may yet be purchased under the plan is $29.1 million.

Stock_Option_Plans_and_ShareBa

Stock Option Plans and Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Option Plans and Share-Based Compensation and 401(k) Plan	'
	Stock Option Plans, Share-Based Compensation and 401(k) Plan
	Description of Share-Based Plans
	Equity Incentive Plan. On May 19, 2009, at our 2009 Annual Meeting of Stockholders (the "2009 Annual Meeting") our stockholders approved the Omnicell, Inc. 2009 Equity Incentive Plan (the "2009 Plan") which authorized 2,100,000 shares to be issued. The 2009 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to our employees, directors and consultants.
	The 2009 Plan succeeded the 1999 Equity Incentive Plan, as amended, the 2003 Equity Incentive Plan, as amended, and the 2004 Equity Incentive Plan (collectively, the "Prior Plans"). No additional awards will be granted under any of the Prior Plans; however, all outstanding stock awards granted under the Prior Plans continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards. For purposes of determining future common shares available for grant, for each share granted as a full-value award, including restricted stock and restricted stock units ("RSUs") performance stock awards, the shares available for grant were reduced by 1.4 shares. Equity awards granted as stock options and stock appreciation rights reduce the shares available for grant by one share.
	On December 16, 2010, at a Special Meeting of Stockholders, our stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2,600,000 shares and to provide that the number of common stock shares available for issuance under the 2009 Plan be reduced by 1.8 shares for each share granted as a full-value award granted on and after October 1, 2010. For each share granted as a full-value award granted prior to October 1, 2010, future shares available for grants under the 2009 Plan were reduced by 1.4 shares. Awards granted as stock options and stock appreciation rights continue to reduce the number of shares available for issuance under the 2009 Plan on a one-for-one basis. On May 21, 2013, at our Annual Meeting of Stockholders, our stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2,500,000 shares.
	Options granted under the 2009 Plan generally become exercisable over periods of up to 4 years, generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter; however our Board of Directors may impose different vesting terms at its discretion on any award. Options under the 2009 Plan generally expire 10 years from the date of grant. We also grant both restricted stock and restricted stock units to participants under the 2009 Plan. The Board of Directors determines the award amount, the vesting provisions and the expiration period (not to exceed ten years) for each grant. Grants of restricted stock to non-employee directors are granted on the date of our annual meeting of stockholders and vest in full on the date of our next annual meeting of stockholders, provided such non-employee director remains a director on such date. The fair value of the stock on the date of issuance is amortized to expense from the date of grant to the date of vesting. RSUs granted to employees generally vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period. We consider the dilutive impact of options, restricted stock and restricted stock units in our diluted net income per share calculation.
	The Board of Directors shall administer the 2009 Plan unless and until the Board of Directors delegates administration to a committee. Our Board of Directors has delegated administration of the 2009 Plan to the Compensation Committee of the Board and the 2009 Plan is generally administered by such committee. The Board of Directors may suspend or terminate the 2009 Plan at any time. The Board of Directors may also amend the 2009 Plan at any time or from time to time. However, no amendment will be effective unless approved by our stockholders after its adoption by the Board of Directors to the extent stockholder approval is necessary to satisfy the applicable listing requirements of NASDAQ.
	If we sell, lease or dispose of all or substantially all of our assets, or we are acquired pursuant to a merger or consolidation, then the surviving entity may assume or substitute all outstanding awards under the 2009 Plan. If the surviving entity does not assume or substitute these awards, then generally the stock awards will immediately and fully vest.
	At December 31, 2013, 3,060,505 shares of common stock were reserved for future issuance under the 2009 Plan. At December 31, 2013, $7.1 million of total unrecognized compensation cost related to non-vested stock options was expected to be recognized over a weighted average period of 2.7 years.
	1997 Employee Stock Purchase Plan
	We have an Employee Stock Purchase Plan (the "ESPP"), under which employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings, up to a maximum of $25,000 of fair value per year. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
	At our 2009 Annual Meeting, the stockholders approved an amendment to the ESPP, which added 2,622,426 shares to the reserve for future issuance. As of December 31, 2013, there was a total of 1,097,998 shares reserved for future issuance under the ESPP. During the year ended December 31, 2013, 450,713 shares of common stock were purchased under the ESPP. As of December 31, 2013, 4,233,557 shares had been issued under the ESPP.
	As of December 31, 2013, our unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $1.2 million and is expected to be recognized over a weighted average period of 0.6 years.
	Share-Based Compensation—Measurement and Disclosure
	We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimate grant date fair value method of accounting in accordance with ASC 718, Stock Compensation. We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued using the Monte Carlo simulation model.
	The impact on our results for share-based compensation was as follows (in thousands):
		Years Ended December 31,
		2013				2012				2011
	Cost of product and service revenues	$	1,241			$	1,011			$	1,398
	Research and development	1,359				889				1,269
	Selling, general and administrative	8,551				7,314				6,832
	Total share-based compensation expense	$	11,151			$	9,214			$	9,499
	We did not capitalize any share-based compensation into inventory during 2013, 2012 and 2011 as it was not material. Income tax (charges) benefits realized from share-based compensation and resulting increases (decreases) to additional paid in capital during 2013, 2012 and 2011 were $2.4 million, $2.6 million and $2.9 million, respectively.
	Valuation Assumptions
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The fair value of shares issued under the employee stock purchase plans is estimated on the date of issuance using the Black-Scholes-Merton model. The weighted average assumptions used for options granted and ESPP in 2013, 2012 and 2011 were as follows:
		Years Ended December 31,
	Stock Option Plans	2013			2012			2011
	Risk-free interest rate(1)	1.2	%		0.9	%		1.6	%
	Dividend yield	—	%		—	%		—	%
	Volatility(2)	43.1	%		45.8	%		48.5	%
	Expected life(3)	5.3 yrs			5.2 yrs			5.2 yrs
		Years Ended December 31,
	Employee Stock Purchase Plan	2013			2012			2011
	Risk-free interest rate(1)	0.2	%		0.2	%		0.5	%
	Dividend yield	—	%		—	%		—	%
	Volatility(2)	35.1	%		38.5	%		40.2	%
	Expected life(3)	0.5 - 2 yrs			0.5 - 2 yrs			0.5 - 2 yrs
	_______________________________________________________________________________
	-1	The risk-free interest rate for both stock options and the ESPP is based on the zero-coupon U.S. Treasury rate curve in effect at the time of the option grant or at the beginning of the ESPP offering period.
	-2	Expected volatility for both stock options and the ESPP reflects a combination of historical and market-based implied volatility consistent with ASC 718 and SEC Staff Accounting Bulletin 107. We determined that the combination of historical and market-based implied volatility provides a more accurate reflection of our market conditions and is more representative of future stock price trends than employing solely historical volatility.
	-3	Represents the period of time that options granted are expected to be outstanding, which is derived from historical data on employee exercise and post-vesting employment termination behavior.
	Share-Based Payment Award Activity
	A summary of option activity under the 2009 Plan for the years ended December 31, 2013, 2012 and 2011 is presented below:
	Options:	Number of Shares			Weighted Average
					Exercise Price
		(in thousands)
	Outstanding at December 31, 2010	4,740			$	12.86
	Granted	494			$	14.57
	Exercised	(413	)		$	8.3
	Expired	(86	)		$	13.59
	Forfeited	(42	)		$	20.76
	Outstanding at December 31, 2011	4,693			$	13.36
	Granted	645			$	14.85
	Exercised	(669	)		$	8.65
	Expired	(84	)		$	14.02
	Forfeited	(115	)		$	21.44
	Outstanding at December 31, 2012	4,470			$	14.06
	Granted	502			$	20.25
	Exercised	(1,686	)		$	12.53
	Expired	(56	)		$	15.66
	Forfeited	(87	)		$	14.68
	Outstanding at December 31, 2013	3,143			$	15.82
	Vested and expected to vest at December 31, 2013	3,114			$	15.79
Exercisable at December 31, 2013	2,078			$	15.11
Outstanding options at December 31, 2013 had a weighted-average remaining contractual life of 5.6 years and an aggregate intrinsic value of $30.8 million. Vested and expected to vest options had a weighted-average remaining contractual life of 5.6 years and an aggregate intrinsic value of $30.6 million. Exercisable options at December 31, 2013 had a weighted-average remaining contractual life of 4.1 years and an aggregate intrinsic value of $22.0 million.
The ranges of outstanding and exercisable options for equity share-based payment awards as of December 31, 2013 were as follows:
Range of Exercise Prices	Number			Weighted				Number			Weighted
	Outstanding			Average Exercise				Exercisable			Average Exercise
				Price of							Price of
				Outstanding							Exercisable
				Options							Options
	(in thousands)							(in thousands)
$6.40 - $10.41	332			$	8.71			332			$	8.71
$10.58 - $10.75	384			$	10.65			384			$	10.65
$11.27 - $13.53	347			$	12.84			291			$	12.77
$13.67 - $14.10	358			$	13.86			143			$	13.94
$14.16 - $15.04	364			$	14.58			167			$	14.67
$15.06 - $17.29	382			$	16.79			106			$	16.51
$17.49 - $20.95	434			$	19.84			369			$	20.12
$21.07 - $23.19	330			$	22.52			104			$	21.5
$23.41 - $26.99	136			$	24.61			106			$	24.76
$29.16 - $29.16	76			$	29.16			76			$	29.16
$6.40 - $29.16	3,143			$	15.82			2,078			$	15.11
As of December 31, 2013, we expect $7.1 million of total unrecognized compensation costs related to unvested options to be recognized over a weighted average period of 2.7 years. The weighted average fair value of options granted was $8.09, $6.13 and $6.47 during 2013, 2012 and 2011, respectively. The intrinsic value of options exercised during 2013, 2012 and 2011 was $14.0 million, $2.8 million and $2.9 million, respectively.
Restricted Stock and Restricted Stock Units
A summary of activity of restricted stock and restricted stock units ("RSUs") granted under the 2009 Plan as of December 31, 2013 is presented below:
	Shares of				Weighted-Average Grant			Restricted Stock Units			Weighted-Average Grant
	Restricted Stock				Date Fair Value Per Share						Date Fair Value
	(in thousands)							(in thousands)
Nonvested at December 31, 2010	77				$	12.91		308			$	12.98
Granted	68				$	14.71		145			$	14.39
Vested	(77		)		$	12.91		(152	)		$	14.26
Forfeited	—				—			(14	)		$	12.82
Nonvested at December 31, 2011	68				$	14.71		287			$	13.03
Granted	67				$	14.19		274			$	14.58
Vested	(78		)		$	14.64		(153	)		$	12.9
Forfeited	—				—			(19	)		$	14.55
Nonvested at December 31, 2012	58				$	14.19		389			$	14.09
Granted	$	55			$	18.2		190			19.87
Vested	$	(61	)		$	14.23		(195	)		14.31
Forfeited	—				—			(22	)		14.08
Nonvested at December 31, 2013	$	52			$	18.43		362			17.15
The fair value of restricted stock is the product of the number of shares granted and the closing market price of our common stock on the grant date. The total fair value of restricted stock grants vested in 2013, 2012 and 2011was $1.1 million, $1.1 million and $1.1 million, respectively. Our unrecognized compensation cost related to nonvested restricted stock is approximately 0.4 million and is expected to be recognized over a weighted average period of 2.0 years .
The fair value of RSUs is the product of the number of shares granted and the closing market price of our common stock on the grant date. The total fair value of RSUs vested in 2013, 2012 and 2011 was $4.4 million, $2.3 million and $2.4 million, respectively. Expected future compensation expense relating to RSUs outstanding on December 31, 2013 is $5.5 million over a weighted- average period of 2.5 years.
Performance-Based Restricted Stock Units
In 2011, we began incorporating performance-based restricted stock units ("PSUs") as an element of our executive compensation plans. For 2011, we granted 100,000 PSUs; however, pursuant to their terms, 120,000 PSUs ultimately became eligible for vesting upon the achievement of a certain level of shareholder return for 2011 as described below. In 2012, we granted 125,000 PSUs of which 62,500 became eligible for vesting upon the achievement of a certain level of shareholder return for 2012 as described below. In 2013, we granted 125,000 PSUs to our executive officers.
Our unrecognized compensation cost related to non-vested performance-based restricted stock units at December 31, 2013 was approximately $1.1 million and is expected to be recognized over a weighted-average period of 1.1 years . For the year ended December 31, 2012, we recognized $1.0 million of compensation expense for the performance-based restricted stock units. For the year ended December 31, 2011, we recognized $0.6 million of compensation expense for the performance-based restricted stock units.
The accounting guidance for awards with market conditions differs from that for awards with service conditions only or service and performance conditions. Because the grant date fair value of an award containing market conditions is calculated as the expected value, averaging over all possible outcomes, the measured expense is amortized over the service period, regardless of whether the market condition is ever actually met.
The fair value of a PSU award is the average of trial-specific values of the award over each of one million Monte Carlo trials. Each trial-specific value is the market value of the award at the end of the one-year performance period discounted back to the grant date. The market value of the award for each trial at the end of the performance period is the product of (a) the per share value of Omnicell stock at the end of the performance period and (b) the number of shares that vest. The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Healthcare Index (the "Index") as shown in the tables below.
Vesting for the PSU awards is based on the percentile placement of our total stockholder return among the companies listed in the Index and time-based vesting. We calculate total stockholder return based on the one year annualized rates of return reflecting price appreciation plus reinvestment of dividends. For PSU awards granted on February 5, 2013 and on March 5, 2013, stock price appreciation is calculated based on the average closing prices of our common stock for the last 20 trading days leading to March 1, 2014 compared to the average closing prices for the 20 trading days ended on the last trading day of 2012. For PSU awards granted in 2011 and 2012, stock price appreciation is calculated based on the average closing prices of the applicable company's common stock for the 20 trading days ending on the last trading day of the year prior to the date of grant as compared to the average closing prices for the 20 trading days ended on the last trading day of the year of grant.
The following table shows the percent of PSUs granted in 2011 and eligible for further time-based vesting based on our percentile placement:
Percentile Placement of Our Total Shareholder Return		% of PSUs Eligible for Time-
		Based Vesting
Below the 35th percentile		—%
At least the 35th percentile, but below the 50th percentile		50%
At least the 50th percentile, but below the 65th percentile		100%
At least the 65th percentile, but below the 75th percentile (1)		110% to 119%
At or above the 75th percentile		120%
_______________________________________________________________________________
(1)               The actual percentage of PSUs eligible for further time-based vesting is based on straight-line interpolation, where, for example, if the ranking is the 70th percentile, then the vesting percentage is 115%.
On January 17, 2012, the Compensation Committee of our Board of Directors confirmed 76.3% as the percentile rank of Omnicell’s 2011 total stockholder return. This resulted in 120% of the 2011 PSU awards, or 120,000 shares, becoming eligible for further time-based vesting. The eligible PSU awards will vest as follows: 25% of the eligible awards for the first year vested immediately on January 17, 2012 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 120,000 shares eligible for time-based vesting under the 2011 PSU awards, 30,000 shares vested during the year ended December 31, 2013.
The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
	Based Vesting
Below the 35th percentile	—%
At least the 35th percentile, but below the 50th percentile	50%
At least the 50th percentile	100%
On January 22, 2013, the Compensation Committee of our Board of Directors confirmed 35.3% as the percentile rank of Omnicell's 2012 total stockholder return. This resulted in 50% of the 2012 PSU awards, or 62,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on January 22, 2013 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 62,500 shares eligible for time-based vesting under the 2012 PSU awards, 31,244 shares vested during the year ended December 31, 2013.
On February 5 and March 5 2013, the Compensation Committee approved PSU awards of 125,000 shares and 12,500 shares, respectively. If the minimum performance threshold is met as determined by the Compensation Committee of the Board of Directors in 2014, the eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares will vest immediately, with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
A summary of activity of the PSUs for the years ended December 31, 2013 and 2012 is presented below:
Performance-based Stock Units	Number of Units			Weighted-
				Average
				Grant Date
				Fair Value Per
				Unit
	(in thousands)
Non-vested, December 31, 2011	100			$	11.15
Granted	135			$	10.94
Vested	(60	)		$	11.15
Forfeited	—			$	—
Non-vested, December 31, 2012	175			$	11
Granted	142			$	14.68
Vested	(57	)		$	11.15
Forfeited	(35	)		$	10.93
Non-vested, December 31, 2013	225			$	13.32
401(k) Plan
We have established a 401(k) tax-deferred savings plan (the "Omnicell Plan"), whereby eligible employees may contribute a percentage of their eligible compensation, but not greater than 75% of their earnings, up to the maximum as required by law. On January 1, 2009, we began matching 401(k) contributions, up to 3% maximum of employee contributions or $1,000, whichever is lower. During the fourth quarter of 2012, the MTS 401(k) tax-deferred savings plan was merged with the Omnicell Plan. For the years ended December 31, 2013, 2012 and 2011, our total 401(k) contributions were $1.1 million, $0.8 million and $0.6 million, respectively.

Segments

Segments	12 Months Ended
	Dec. 31, 2013
Segments [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Segments
	Beginning with the acquisition of MTS, which was completed on May 21, 2012, we have organized our business into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers and Non-Acute Care, which primarily includes products and services sold to customers outside of hospital settings.
	The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
	Since 1992, Omnicell has provided automation and business information solutions to acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of the acute care environment in hospitals. As the acute care market evolves, we see opportunities to provide medication adherence solutions, which were added to our product line through the acquisition of MTS, to the acute care market as well. A portion of our organization structure and management processes will continue to be structured to optimize sales and service of solutions to the acute care market.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. A portion of our organization structure and management processes will continue to be structured to optimize the product, sales, and service of solutions to the non-acute care market.
	In 2012, we realigned our management reporting structure to report sales of Omnicell's dispensing systems and other related business transactions into long-term care pharmacies and facilities. Accordingly, the operations of this portion of our activities are now being reflected as a part of the Non-Acute Care segment for the year ended December 31, 2012 and 2013. The impact of this reporting structure change on the year ended December 31, 2011 was immaterial to our overall reported results.
	We believe that legislative changes and economic pressures to manage costs will cause healthcare organizations to manage the health of patients across the continuum of care regardless of the setting in which the care is provided. We believe we have the capabilities and market position to provide the tools needed by our customers to manage medications across the continuum of care. But we also believe that the inherent differences between medication management workflows in acute care settings and non-acute care settings will cause our product solutions and marketing strategies to be managed separately for these two customer segments.
	In the second quarter of 2013, our management changed its methodology for allocating certain expenses to our reportable segments. We have reclassified segment operating results for the years ended December 31, 2012 to conform to the 2013 presentation. For the years ended December 31, 2013, 2012 and 2011 the contributions of our segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		December 31,									December 31,									December 31,
		2013									2012									2011
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total			Acute Care			Total
	Net revenues from external customers	$	284,666		$	95,919		$	380,585		$	260,160		$	53,867		$	314,027		$	245,535		$	245,535
	Cost of revenues	122,816			54,370			177,186			111,599			31,840			143,439			109,751			109,751
	Gross profit	$	161,850		$	41,549		$	203,399		$	148,561		$	22,027		$	170,588		$	135,784		$	135,784
	Gross margin %	56.9		%	43.3		%	53.4		%	57.1		%	40.9		%	54.3		%	55.3		%	55.3		%
	Operating expenses	131,811			36,289			168,100			127,467			15,995			143,462			119,562			119,562
	Income from operations	$	30,039		$	5,260		$	35,299		$	21,094		$	6,032		$	27,126		$	16,222		$	16,222
	Operating margin %	10.6		%	5.5		%	9.3		%	8.1		%	11.2		%	8.6		%	6.6		%	6.6		%
	Interest and other income (expense), net							(270		)							(51		)				(133		)
	Income before provision for income taxes							35,029									27,075						16,089
	Provision for income taxes							11,050									10,897						5,700
	Net income							$	23,979								$	16,178					$	10,389
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the closing date of acquisition.
	At December 31, 2013, 2012, and 2011 segment assets, depreciation and amortization, and capital expenditures were as follows (amounts in thousands):
		December 31,									December 31,									December 31,
		2013									2012									2011
		Acute Care			Non-Acute Care (1)			Total			Acute Care			Non-Acute Care (1)			Total			Acute Care			Total
	Segment Assets	$	263,154		$	229,347		$	492,501		$	235,186		$	206,633		$	441,819		$	363,849		$	363,849
	Depreciation/Amortization	$	11,236		$	7,129		$	18,365		$	9,017		$	4,308		13,325			7,983			7,983
	Capital Expenditures	$	4,392		$	7,943		$	12,335		$	13,234		$	1,953		$	15,187		$	8,685		$	8,685
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.
	For the year ended December 31, 2012, the Non-Acute Care cost of revenues included $1.7 million of acquisition-related charges primarily associated with the step-up to the estimated fair value of inventory acquired from MTS and consumed in the normal sales cycle of our business. The Non-Acute Care operating expenses included $0.9 million of acquisition-related charges primarily associated with severance expenses. For the year ended December 31, 2012, the Acute Care operating expenses included $2.3 million of acquisition-related charges for transaction costs, required to be expensed under ASC 805, Business Combinations.

Credit_Agreement_Notes

Credit Agreement (Notes)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Credit Agreement [Text Block]	'
	Credit Agreement
	In September 2013, we entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. The Credit Agreement provides for a $75.0 million revolving credit facility with a $10.0 million letter of credit sub-limit. Loans under the Credit Agreement mature on September 25, 2018. The Credit Agreement permits us to request one or more increases in the aggregate commitments provided that such increases do not exceed $25.0 million in the aggregate. We expect to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. Our obligations under the Credit Agreement are guaranteed by certain of our domestic subsidiaries and secured by substantially all of our and the subsidiary guarantors’ assets. To date, we have not yet drawn any funds under the credit facility.
	Amounts drawn under the Credit Agreement bear interest, at our election, at a Eurodollar rate plus a margin of 1.75% per annum, or an alternate base rate equal to the highest of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) LIBOR for an interest period of one month plus 1.75%. We are required to pay a commitment fee of 0.25% per annum on the aggregate undrawn amount of the commitments under the credit facility.
	The Credit Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require us to, among other things, maintain a maximum consolidated total leverage ratio and a minimum consolidated fixed charge coverage ratio, in each case, as of the last day of each fiscal quarter. We were in full compliance with all covenants at December 31, 2013.

Asset_Impairment_Notes

Asset Impairment (Notes)	12 Months Ended
	Dec. 31, 2013
Asset Impairment [Abstract]	'
Asset Impairment Charges [Text Block]	'
	Asset Impairment
	As part of the continuing integration of MTS, during the first quarter of 2013, we reorganized our management team, including the software development department, within the Non-Acute Care segment. Through the end of the first quarter of 2013, the Non-Acute Care segment had capitalized approximately $1.8 million of software development costs associated with a software solution under development which was intended to assist pharmacies in manual packaging of prescriptions. In connection with our financial statement close process for the quarter ended March 31, 2013, our management reassessed the viability of this project and the net realizable value of capitalized costs in light of its decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities will need to be added to the product before commercialization. This redesign is intended to provide a more robust global platform providing larger scalability and significant functionality not contained in our current beta version. As such, we have determined we could no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we charged these costs, in the amount of $1.8 million, or $0.03 per diluted share, net of tax, to expense as a component of research and development in the accompanying consolidated statements of operations.

Schedule_II

Schedule II	12 Months Ended
	Dec. 31, 2013
Schedule II [Abstract]	'
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	'
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)
	Allowances deducted from assets:		Balance at		Additions		Charged			Describe	Deductions			Describe	Balance at
			beginning of		charged to		(credited)			charged to				deductions	end of year
			year		costs and		to other			other
					expenses (2)		accounts			accounts
	For the year ended December 31, 2011
	Accounts receivable(1)		$	497	$	63	$	(96	)	-3	$	(21	)	-4	$	443
	Investment in sales-type leases(1)		411		—		(22		)	-5	(105		)	-4	284
	Total allowances deducted from assets		$	908	$	63	$	(118	)		$	(126	)		$	727
	For the year ended December 31, 2012
	Accounts receivable(1)		$	443	$	316	$	(57	)	-3	$	20		-4	$	722
	Investment in sales-type leases(1)		284		425		—			-3	(102		)	-4	607
	Total allowances deducted from assets		$	727	$	741	$	(57	)		$	(82	)		$	1,329
	For the year ended December 31, 2013
	Accounts receivable(1)		$	722	195		(67		)	-3	(360		)	-4	490
	Investment in sales-type leases (1)		607		49		—				(489		)	-4	167
	Total allowances deducted from assets		$	1,329	$	244	$	(67	)		$	(849	)		$	657
	_______________________________________________________________________________
	-1	Allowance for doubtful accounts.
	-2	Represents amounts charged to bad debt expense.
	-3	Represents amounts credited to bad debt expense.
	-4	Represents amounts written-off, net of recoveries.
	-5	Represents amounts credited to bad debt expense and lease receivable adjustment.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	'
	Principles of consolidation.  The consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates.  The preparation of financial statements in accordance with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and cash equivalents. We classify investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. Our cash and cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities from overnight to three months. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our surplus funds. We have not experienced any credit losses from our cash investments.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair value of financial instruments.  We value our financial assets and liabilities on a recurring basis using the fair value hierarchy established in Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures.
	ASC 820 describes three levels of inputs that may be used to measure fair value, as follows:
	Level 1 inputs, which include quoted prices in active markets for identical assets or liabilities;
	Level 2 inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and
	Level 3 inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
	At December 31, 2013 and December 31, 2012, our financial assets utilizing Level 1 inputs included cash equivalents. For these items, quoted market prices are readily available and fair value approximates carrying value. We do not currently have any material financial instruments utilizing Level 2 or Level 3 inputs.
Marketable Securities, Policy [Policy Text Block]	'
	Classification of marketable securities. Marketable securities for which we have the intent and ability to hold to maturity are classified as held-to-maturity, with carrying value at amortized cost, including accrued interest. We do not hold securities for purposes of trading. However, securities held as investments for the indefinite future, pending future spending requirements are classified as available-for-sale, with carrying value at fair value and any unrealized gain or loss recorded to other comprehensive income until realized. We held $65.7 million and $38.9 million of money market mutual funds as available-for-sale cash equivalents as of December 31, 2013 and 2012, respectively.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition.    We earn revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues related to consumable products are reported net of discounts provided to our customers. Our customer arrangements typically include one or more of the following deliverables:
	•	Products—Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
	•	Software—Additional software applications that enable incremental functionality of our equipment.
	•	Installation—Installation of equipment as integrated systems at customers' sites.
	•	Post-installation technical support—Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
	•	Professional services—Other customer services such as training and consulting.
	We recognize revenue when the earnings process is complete, based upon our evaluation of whether the following four criteria have been met:
	•	Persuasive evidence of an arrangement exists. We use signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, we use a signed services agreement and a statement of work to evidence an arrangement.
	•	Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that we have delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, we recognize revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install our equipment at end user customer facility, we recognize revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met since we do not allow for rights of return or refund. For new distributors, where we have not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install our equipment at the end user facility. For the sale of consumable blister cards, we recognize revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from our facilities. Assuming all other revenue criteria are met, we recognize revenue for support services ratably over the related support services contract period. We recognize revenue on training and professional services as they are performed.
	•	Fee is fixed or determinable. We assess whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. We have established a history of collecting under the original contract without providing concessions on payments, products or services.
	•	Collection is probable. We assess the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in our judgment, collection of a fee is not probable, we defer the revenue until the uncertainty is removed, which generally means revenue is recognized upon our receipt of cash payment assuming all other revenue criteria are met. Our historical experience has been that collection from our customers is generally probable.
	In arrangements with multiple deliverables, assuming all other revenue criteria are met, we recognize revenue for individual delivered items if they have value to the customer on a standalone basis.We allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires us to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, we use vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. We consider VSOE to exist when approximately 80% or more of our standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). We have established VSOE of the selling price for our post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, our offerings and market strategy differ from those of our competitors, such that we cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, we use our best estimates of selling prices ("BESP"). We determine BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. We regularly review and update our VSOE and BESP information.
	The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement.
	We also use the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered.
	A portion of our sales are made through multi-year lease agreements. Under sales-type leases, we recognize revenue for our hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once our installation obligations have been met. We optimize cash flows by selling a majority of our non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold. Some of our sales-type leases, mostly those relating to U.S. government hospitals, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method
Receivables, Policy [Policy Text Block]	'
	Accounts receivable and notes receivable (net investment in sales type leases). We actively manage our accounts receivable to minimize credit risk. We typically sell to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. We continually monitor and evaluate the collectability of our trade receivables based on a combination of factors. We record specific allowances for doubtful accounts when we become aware of a specific customer's impaired ability to meet its financial obligation to us, such as in the case of bankruptcy filings or deterioration of financial position.
	Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when we make a final determination that there is no reasonable expectation of recovery. Estimates are used in determining our allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While we believe that our allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future.
	The retained in-house leases discussed above are considered financing receivables. Our credit policies and evaluation of credit risk and write-off policies are applied alike to trade receivables and the net-investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Financing receivables which are reserved are generally transferred to cash-basis accounting so that revenue is recognized only as cash is received. However, the cash basis accounts continue to accrue interest.
Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block]	'
	Sales of accounts receivable.  We record the sale of our accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets. During the years ended 2013, 2012 and 2011, we transferred non-recourse accounts receivable totaling $41.3 million, $60.9 million and $46.9 million, respectively, which approximated fair value, to leasing companies on a non-recourse basis. At December 31, 2013, 2012 and 2011, accounts receivable included approximately $0.1 million, $0.7 million and $0.2 million, respectively, due from third-party leasing companies for transferred non-recourse accounts receivable.
Commissions, Policy [Policy Text Block]	'
	Commissions. Sales commissions generally are earned by and paid to our sales team upon order receipt, but are recognized in expense at the time of revenue recognition. Before they are recognized as expense they are recorded as prepaid commissions, which are a component of prepaid expenses.
Inventory, Policy [Policy Text Block]	'
	Inventory. Inventories are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or market. Cost elements included in inventory are direct labor and materials plus applied overhead. We routinely assess on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. We write down our inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than we projected, additional inventory write-downs may be required.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and equipment. Property and equipment less accumulated depreciation are stated at historical cost. Our expenditures for property and equipment are for computer equipment and software used in the administration of our business, and for leasehold improvements to our leased facilities. We also develop molds and dies used in long-term manufacturing arrangements with suppliers, and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 years
	Equipment	3 - 5 years
	We capitalize costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Software obtained for internal use has generally been enterprise-level business and finance software that we customize to meet our specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. At December 31, 2013 and December 31, 2012, we had $4.8 million and $5.4 million, respectively, of costs related to application development of enterprise-level software included in property and equipment.
Research, Development, and Computer Software, Policy [Policy Text Block]	'
	Software development costs. We capitalize software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. We establish feasibility when we complete a working model and amortize development costs over the estimated lives of the related products ranging from three to five years. During 2013 and 2012, we capitalized software development costs of $7.8 million and $5.0 million, respectively, which are included in other assets. For the years ended December 31, 2013, 2012 and 2011, we charged to cost of revenues $3.2 million, $2.3 million, and $1.6 million, respectively, for amortization of capitalized software development costs. All development costs prior to the completion of a working model are recognized as research and development expense.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Valuation and impairment of goodwill, other intangible assets and other long lived assets. We account for goodwill and other intangible assets in accordance with ASC 350, Intangibles—Goodwill and Other ("ASC 350). For the initial recognition and measurement of Goodwill and Intangibles resulting from acquisitions, we use the guidance in ASC 805, Business Combinations.
	Under ASC 350, Intangibles - Goodwill and Other, goodwill and intangible assets with an indefinite life are not subject to amortization but are tested for impairment at least annually or more frequently if indicators of impairment exist. ASC 350 defines impairment as the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The provisions of ASC 350 require that an entity assign its recorded goodwill to each of its reporting units and test each reporting unit's goodwill for impairment. We have determined that we have two reporting units: the Acute Care and the Non-Acute Care segments.
	In accordance with ASC 350, we have the option, in any period, to first assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill, or bypass the qualitative assessment and proceed directly to performing the two-step quantitative goodwill impairment test. The first step ("step 1") involves comparing each reporting unit's estimated fair value to its carrying value, including goodwill, to identify potential impairment. If the estimated fair value of a reporting unit exceeds its carrying value, there is no indication of impairment and no further test is required. If the carrying value exceeds the estimated fair value, there is an indication of potential impairment and the second step is required to be performed to measure the amount of impairment.
	In the fourth quarter of 2013, we elected to perform step 1 to determine whether it is more likely than not that the fair values of our reporting units are less than their carrying amounts. While the ultimate responsibility rests with management, we engaged the services of an independent, third-party valuation specialist to assist in determining the fair values of our reporting units. We used a combination of a discounted cash flow model (“DCF”) which utilizes the present value of cash flows to estimate fair value (also known as the income approach) and comparisons to publicly traded companies’ market multiples (also known as the market approach).
	Under the DCF model, the future cash flows for our reporting units were projected based on management’s projections, at that time, of future revenues, operating income and other factors such as working capital and capital expenditures. We also took into account market factors and industry conditions affecting our business. We used significant judgment to estimate the amount and timing of future cash flows from our reporting units and the relative risk of achieving those cash flows. Forecasts of future operations are based, in part, on operating results and our expectations as to future market conditions. The discount rate used in our DCF model was based on a weighted-average cost of capital determined from relevant market comparisons and adjusted for specific reporting unit risks (primarily the risk of achieving projected operating cash flows). A terminal value growth rate was applied to the final year of the respective cash flows for both reporting units to arrive at an estimate of fair value under the income approach. The estimated fair values of our reporting units determined under the income approach exceeded their carrying values.
	We used the market approach to corroborate the values estimated under the income approach. Under the market approach, we estimated the fair values of our reporting units based on financial information on companies that we deemed were comparable to our business. Based on publicly available information, we calculated the comparable companies’ market multiples of earnings before interest, taxes, depreciation and amortization, and stock option expense and factored in a control premium. The estimated fair values of our reporting units determined under the market approach exceeded their carrying values.
	Finally, we compared the estimated fair values of our reporting units to our September 30, 2013 total public market capitalization and assessed implied control premiums. Based on the aforementioned, we concluded that the estimated fair value determined for both our reporting units was reasonable. In each case, the estimated fair values of our reporting units exceeded their respective carrying values and, as such, we concluded that goodwill assigned to our Acute Care and Non-Acute Care segments was not impaired. In addition, we did not note any indications of goodwill impairment as of December 31, 2013
	In 2012, we opted to perform a qualitative assessment of factors to determine if goodwill had been impaired as of December 31, 2012. For both the Acute Care and Non-Acute Care segments, we considered the following qualitative factors:
	•	Macroeconomic conditions such as general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates or other developments in equity and credit markets;
	•	Industry and market considerations such as changes in the environment in which we operate, an increased competitive environment, a decline in market-dependent multiples or metrics (consider in both absolute terms and relative to peers), a change in the market for our products or services, or a regulatory or political development;
	•	Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on earnings and cash flows;
	•	Overall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods;
	•	Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy or litigation; and
	•	Events affecting a reporting unit such as a change in the composition or carrying amount of its net assets, a more-likely-than-not expectation of selling or disposing all, or a portion, of a reporting unit, the testing for recoverability of a significant asset group within a reporting unit or recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit.
	Upon completion of our qualitative assessment conducted in the fourth quarter of 2012, management concluded that it was more likely than not the fair values of both the Acute and Non-Acute reporting units exceeded their carrying values including the respective amounts of goodwill. In addition, management did not note any other indicators of goodwill impairment as of December 31, 2012.
	We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. We review long-lived assets and certain purchased intangibles for impairment whenever events or changes in circumstances indicate that we will not be able to recover the asset's carrying amount. Recoverability of an asset is measured by comparing its carrying amount to the expected future undiscounted cash flows expected to result from the use and eventual disposition of that asset, excluding future interest costs that would be recognized as an expense when incurred. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair market value. Significant management judgment is required in:
	•	identifying a triggering event that arises from a change in circumstances;
	•	forecasting future operating results; and
	•	estimating the proceeds from the disposition of long-lived or intangible assets.
	Significant management judgment is also required for initial recognition and measurement of goodwill and other intangibles assets resulting from business combinations in accordance with ASC 805. Management must assess the extent to which identified other intangibles assets are properly includable (and with the appropriate fair value) or properly excludable, by applying the recognition criteria. This judgment affects not only the other intangible assets but the remainder calculation of goodwill. The assessment of useful life for each acquired intangible impacts future financial position and operating performance through amortization expense.
Revenue Recognition, Deferred Revenue [Policy Text Block]	'
	Deferred service revenue and deferred gross profit. Deferred service revenue and deferred gross profit arise when customers are billed for products and/or services in advance of revenue recognition. Our deferred gross profit, classified as a current liability, consists primarily of unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment, and the unearned revenue for software licenses. Our deferred service revenue, separated into current and long-term liabilities, consists of the unearned portion of service contracts for which revenue is recognized over their duration.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Valuation of share-based awards. We account for share-based compensation plans in accordance to the provisions of ASC 718, Stock Compensation. We estimate the fair value of our employee stock awards at the date of grant using certain subjective assumptions, such as expected volatility, which is based on a combination of historical and market- based implied volatility, and the expected term of the awards which is based on our historical experience of employee stock option exercises including forfeitures. Our valuation assumptions used in estimating the fair value of share-based awards may change in future periods. We recognize the fair value of awards over their vesting period or requisite service period. In addition, we calculate our pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718.
Income Tax, Policy [Policy Text Block]	'
	Accounting for income taxes. We record an income tax provision for the anticipated tax consequences of the reported results of operations. In accordance with GAAP, the provision for income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities, and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, we will incur a benefit or detriment on our income tax expense in the period of change. If we were to determine that all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
	In accordance with ASC 740, Income Taxes, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management's expectations could have a material impact on our financial condition and operating results.
	Please refer to Note 14, Income Taxes, for further information.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping costs. Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense. Such shipping and handling expenses totaled $6.1 million, $4.1 million, and $2.7 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Lease, Policy [Policy Text Block]	'
	Operating leases. We lease our buildings under operating leases accounted for in accordance with ASC 840, Leases.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation. We translate the assets and liabilities of our non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity.
	Currency forward contracts. From time to time we enter into foreign currency forward contracts to protect our business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and our foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value in the balance sheet. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income (a component of stockholders' equity) or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. As of December 31, 2013 and 2012, we had no foreign currency forward contracts which qualify for hedge accounting.
Segment Reporting, Policy [Policy Text Block]	'
	Segment information. Prior to the acquisition of MTS, we managed our business on the basis of a single operating segment, and a single reporting unit within that segment per ASC 280, Segment Reporting. Beginning with the acquisition of MTS, which was completed in May 2012, we have organized our business into two operating business segments: Acute Care, which primarily includes products and services sold to hospital customers and Non-Acute Care, which primarily includes products and services sold to customers outside of the hospital settings.
	The Acute Care segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems. The Non-Acute Care segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services, but also includes medication dispensing systems sold to non-acute care pharmacies and facilities. We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations.
	Since 1992, Omnicell has provided automation and business information solutions to acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of the acute care environment in hospitals. As the acute care market evolves, we see opportunities to provide medication adherence solutions, which were added to our product line through the acquisition of MTS. A portion of our organization structure and management processes will continue to be structured to optimize sales and service of solutions to the acute care market.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies. A portion of our organization structure and management processes will continue to be structured to optimize the product, sales, and service of solutions to the non-acute care market.
	In 2012, we realigned our management reporting structure to report sales of Omnicell's dispensing systems and other related business transactions to long-term care pharmacies and facilities. Accordingly, the operations of this portion of our activities are now being reflected as a part of the Non-Acute Care segment for the year ended December 31, 2012. Non-Acute Care segment operating results were immaterial for the year ended December 31, 2011.
	Effective in the second quarter of 2013, our management changed its methodology for allocating certain expenses to our reportable segments. The impact of this change in methodology in our 2012 segment operating results was immaterial.
	Substantially all of our long-lived assets are located in the United States. For the years ended December 31, 2013 and 2012, all of our total revenues and gross profits were generated by both our Acute Care and Non-Acute Care segments and no one customer accounted for greater than 10% of our revenues. For the year ended December 31, 2011, all of our total revenues and gross profits were generated by the Acute Care segment and no one customer accounted for greater than 10% of our revenues.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Adopted Accounting Standards
	In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("AOCI"), which aims to improve the reporting of reclassifications out of AOCI. This update requires an entity to report the effect of significant reclassifications out of AOCI on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. We adopted this guidance in the first quarter of 2013, without any impact to our financial position, operating results or cash flows.
	Recently Issued Accounting Standards
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We will adopt the amendments in ASU 2013-11 in the first quarter of 2014, and do not expect the adoption to have a material impact on our financial position, operating results or cash flows.
Earnings Per Share, Policy [Policy Text Block]	'
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method.

Business_Acquisition_Tables

Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013							Dec. 31, 2012	Dec. 31, 2012
								MTS-Medication Technologies [Member]	Pandora [Member]
Business Acquisition [Line Items]	'							'	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'							'	'
	The total acquisition price was approximately $158.3 million and was allocated as follows (in thousands):								u
		Fair value acquired
	Cash including restricted cash	$	2,000
	Accounts receivable	7,403
	Inventory	11,726
	Deferred tax assets and other current assets	2,894
	Total current assets	24,023
	Property and equipment	9,807
	Intangible assets	83,900
	Goodwill	82,800
	Other non-current assets	308
	Total assets	200,838
	Current liabilities	(7,917		)
	Non-current deferred tax liabilities	(33,386		)
	Other non-current liabilities	(1,223		)
	Net assets acquired	$	158,312
	Cash consideration, fair value	$	158,312
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	'							'	'
	Details of acquired intangibles are as follows (in thousands, except for years):
		Fair value acquired			Useful Life (years)	First year amortization expense
	Trade name	$	6,800		12	$	567
	Customer relationships	50,500			28 to 30	1,707
	Acquired technology	26,600			20	1,330
	Intangibles acquired	$	83,900			$	3,604
	Weighted average life of intangibles				25.14
Business Acquisition, Pro Forma Information [Table Text Block]	'							'	'

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 years
	Equipment	3 - 5 years
	Property and equipment consist of the following (in thousands):
		December 31,			December 31,
		2013			2012
	Equipment	$	40,180		$	32,528
	Furniture and fixtures	5,260			5,126
	Leasehold improvements	7,394			6,992
	Purchased software	20,199			19,870
	Construction in process	2,649			2,693
		75,682			67,209
	Accumulated depreciation and amortization	(40,428		)	(33,102		)
	Property and equipment, net	$	35,254		$	34,107

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Income Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Years Ended December 31
		2013		2012		2011
	Basic:
	Net income	$	23,979	$	16,178	$	10,389
	Weighted average shares outstanding — basic	34,736		33,307		33,123
	Net income per share — basic	$	0.69	$	0.49	$	0.31
	Diluted:
	Net income	$	23,979	$	16,178	$	10,389
	Weighted average shares outstanding — basic	34,736		33,307		33,123
	Add: Dilutive effect of employee stock plans	1,041		906		980
	Weighted average shares outstanding — diluted	35,777		34,213		34,103
	Net income per share — diluted	$	0.67	$	0.47	$	0.3

Cash_and_Cash_Equivalents_Shor1

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]	'
	Cash and cash equivalents consist of the following significant investment asset classes, with disclosure of amortized cost, gross unrealized gains and losses, and fair value as of December 31, 2013 and December 31, 2012 (in thousands):
		December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market funds	65,708		—		—		65,708		65,708		Available for sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
		December 31, 2012
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	23,422	$	—	$	—	$	23,422	$	23,422	N/A
	Money market funds	38,892		—		1		38,891		38,891		Available for sale
	Total cash and cash equivalents	$	62,314	$	—	$	1	$	62,313	$	62,313
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
	The following table displays the financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Significant Other		Significant		Total Fair
		Markets for Identical		Observable Inputs		Unobservable		Value
		Instruments		(Level 2)		Inputs
		(Level 1)				(Level 3)
	At December 31, 2013	$	—
	Money market funds	$	65,708	$	—	$	—	$	65,708
	Total	$	65,708	$	—	$	—	$	65,708
	At December 31, 2012
	Money market funds	$	38,891	$	—	$	—	$	38,891
	Total	$	38,891	$	—	$	—	$	38,891

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories consist of the following (in thousands):
		December 31,		December 31,
		2013		2012
	Raw materials	$	10,765	$	9,994
	Work in process	534		385
	Finished goods	20,158		16,524
	Total	$	31,457	$	26,903

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 years
	Equipment	3 - 5 years
	Property and equipment consist of the following (in thousands):
		December 31,			December 31,
		2013			2012
	Equipment	$	40,180		$	32,528
	Furniture and fixtures	5,260			5,126
	Leasehold improvements	7,394			6,992
	Purchased software	20,199			19,870
	Construction in process	2,649			2,693
		75,682			67,209
	Accumulated depreciation and amortization	(40,428		)	(33,102		)
	Property and equipment, net	$	35,254		$	34,107

Net_Investment_in_SalesType_Le1

Net Investment in Sales-Type Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Capital Leases, Net Investment in Sales Type Leases [Abstract]	'
sales type lease investment [Table Text Block]	'
	The components of our net investment in sales-type leases are as follows (in thousands):
		December 31,		December 31,
		2013		2012
	Net minimum lease payments to be received	$	18,172	$	19,665
	Less unearned interest income portion	1,455		1,205
	Net investment in sales-type leases	16,717		18,460
	Less current portion(1)	5,232		5,232
	Non-current net investment in sales-type leases(2)	$	11,485	$	13,228
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	The minimum lease payments under sales-type leases as of December 31, 2013 were as follows (in thousands):
	2014	$5,851
	2015	4,857
	2016	3,618
	2017	2,710
	2018	1,136
	Total	$18,172
Allowance for Credit Losses on Financing Receivables [Table Text Block]	'
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest, as of December 31, 2013 and December 31, 2012 (in thousands):
		Allowance for Credit Losses		Recorded Investment		Recorded Investment
				in Sales-type Leases Gross		in Sales-type Leases Net
	Credit loss disclosure for December 31, 2013:
	Accounts individually evaluated for impairment	$	—	$	—	$	—
	Accounts collectively evaluated for impairment	167		16,884		16,717
	Ending balances: December 31, 2013	$	167	$	16,884	$	16,717
	Credit loss disclosure for December 31, 2012:
	Accounts individually evaluated for impairment	$	489	$	489	$	—
	Accounts collectively evaluated for impairment	118		18,578		18,460
	Ending balances: December 31, 2012	$	607	$	19,067	$	18,460
Schedule of Credit Losses Related to Financing Receivables, Noncurrent [Table Text Block]	'
	The following table summarizes the activity for the allowance for credit losses account for the investment in sales-type leases for the year ended December 31, 2013 (in thousands):
		Year Ended
		December 31, 2013
	Allowance for credit losses, December 31, 2012	607
	Current period provision (reversal)	49
	Direct write-downs charged against the allowance	(413	)
	Recoveries of amounts previously charged off	(76	)
	Allowance for credit losses at December 31, 2013	167

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	Activity in goodwill by reporting units, which are the same as our operating segments, for the year ended December 31, 2013 consists of the following (in thousands):
		Goodwill at December 31, 2012			Adjustments to Goodwill			Goodwill at December 31, 2013
	Reporting units:
	Acute Care	$	28,543		$	—		$	28,543
	Non-Acute Care	82,864			(64		)	82,800
	Total	$	111,407		$	(64	)	$	111,343
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Finite-life intangible assets at these dates consist of the following (in thousands):
		31-Dec-13							December 31, 2012
		Gross					Net		Gross		Net
		Carrying		Accumulated			Carrying		Carrying	Accumulated	Carrying	Amortization
		Amount		Amortization			Amount		Amount	Amortization	Amount	Life
	Finite-lived intangibles:
	Customer relationships	54,730		5,236			49,494		54,730	3,081	51,649	5-30 years
	Acquired technology	27,580		2,598			24,982		27,580	1,128	26,452	3-20 years
	Patents	1,493		254			1,239		1,217	259	958	20 years
	Trade name	6,890		1,003			5,887		6,890	414	6,476	3-12 years
	Non-compete agreements	60		60			—		60	45	15	3 years
	Total finite-lived intangibles	90,753		9,151			81,602		90,477	4,927	85,550
	Estimated annual expected amortization expense of the finite-lived intangible assets at December 31, 2013 was as follows (in thousands):
	2014	4,229
	2015	4,204
	2016	3,854
	2017	3,818
	2018	3,711
	Thereafter	61,786
	Total	$	81,602

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Other Assets [Abstract]	'
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	'
	Other assets consist of the following (in thousands):
		December 31,
		2013		2012
	Capitalized software development costs, net of accumulated amortization of $10,547 and $7,329 in 2013 and 2012, respectively	$	13,660	$	11,037
	Technology license	2,350		2,800
	Long-term deposits	682		694
	Other assets	1,245		1,247
	Total	$	17,937	$	15,778

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities consist of the following (in thousands):
		December 31,		December 31,
		2013		2012
	Rebates and lease buyouts	$	1,699	$	3,179
	Advance payments from customers	4,971		2,829
	Accrued Group Purchasing Organization (GPO) fees	2,324		2,278
	Technology license purchase obligation, current portion	1,500		1,750
	Taxes payable	1,664		555
	Other	1,588		1,397
	Total	$	13,746	$	11,988

Deferred_Gross_Profit_Tables

Deferred Gross Profit (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Gross Profit [Abstract]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	Deferred gross profit consists of the following (in thousands):
		December 31,			December 31,
		2013			2012
	Sales of medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$	29,040		$	30,138
	Cost of revenues, excluding installation costs	(9,083		)	(9,366		)
	Deferred gross profit	$	19,957		$	20,772

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	At December 31, 2013, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	2014	$	5,787
	2015	5,476
	2016	5,150
	2017	4,468
	2018	4,298
	Thereafter	16,601
	Total	$	41,780

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
	The following is a geographical breakdown of income before the provision for income taxes (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Domestic	$	34,678		$	25,794		$	16,177
	Foreign	351			1,281			(88		)
	Total income before provision for income taxes	$	35,029		$	27,075		$	16,089
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The provision for income taxes consists of the following (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	8,218		$	7,181		$	4,285
	State	1,621			1,006			896
	Foreign	447			154			(70		)
	Total current	10,286			8,341			5,111
	Deferred:
	Federal	1,287			2,169			1,116
	State	(263		)	651			(527		)
	Foreign	(260		)	(264		)	—
	Total deferred	764			2,556			589
	Total provision for income taxes	$	11,050		$	10,897		$	5,700
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The provision for income taxes differs from the amount computed by applying the statutory federal tax rate as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	U.S. federal tax provision at statutory rate	$	12,260		$	9,476		$	5,631
	State taxes	883			1,077			240
	Non-deductible expenses	297			530			481
	Acquisition costs	—			431			—
	Share-based compensation expense	407			403			443
	Research tax credits	(1,430		)	—			(755		)
	Domestic production deduction	(816		)	(601		)	(271		)
	Other	(551		)	(419		)	(69		)
	Total	$	11,050		$	10,897		$	5,700
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of our deferred tax assets (liabilities) are as follows (in thousands):
		December 31,
		2013			2012
	Deferred tax assets (liabilities):
	Tax credit carry forwards	$	3,160		$	2,990
	Inventory related items	2,947			2,900
	Deferred revenue	11,074			11,497
	Stock compensation	7,447			9,331
	Loss carry forwards	64			53
	Other, net	5			69
	Subtotal	24,697			26,840
	Less: valuation allowance	(39		)	(39		)
	Total net deferred tax assets	24,658			26,801
	Reserves and accruals	(353		)	(573		)
	Depreciation and amortization	(38,681		)	(39,840		)
	Total deferred tax liabilities	(39,034		)	(40,413		)
	Net deferred tax liabilities	$	(14,376	)	$	(13,612	)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	he aggregate changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the three years ended December 31, 2013 is as follows (in thousands):
	Balance as of December 31, 2010	$	5,431
	Decreases related to tax positions taken during the prior period	(88		)
	Increases related to tax positions taken during the current period	453
	Balance as of December 31, 2011	$	5,796
	Increases related to tax positions taken during a prior period	43
	Increases related to tax positions related to MTS	1,066
	Increases related to tax positions taken during the current period	422
	Decreases related to settlements	(33		)
	Decreases related to expiration of statute of limitations	(379		)
	Balance as of December 31, 2012	$	6,915
	Increases related to tax positions taken during a prior period	406
	Decreases related to tax positions taken during the prior period	(79		)
	Increases related to tax positions taken during the current period	764
	Decreases related to expiration of statute of limitations	(32		)
	Balance as of December 31, 2013	$	7,974

Stock_Option_Plans_and_ShareBa1

Stock Option Plans and Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule share-based compensation costs	'
	The impact on our results for share-based compensation was as follows (in thousands):
		Years Ended December 31,
		2013				2012				2011
	Cost of product and service revenues	$	1,241			$	1,011			$	1,398
	Research and development	1,359				889				1,269
	Selling, general and administrative	8,551				7,314				6,832
	Total share-based compensation expense	$	11,151			$	9,214			$	9,499
Schedule of valuation assumptions	'
	The weighted average assumptions used for options granted and ESPP in 2013, 2012 and 2011 were as follows:
		Years Ended December 31,
	Stock Option Plans	2013			2012			2011
	Risk-free interest rate(1)	1.2	%		0.9	%		1.6	%
	Dividend yield	—	%		—	%		—	%
	Volatility(2)	43.1	%		45.8	%		48.5	%
	Expected life(3)	5.3 yrs			5.2 yrs			5.2 yrs
		Years Ended December 31,
	Employee Stock Purchase Plan	2013			2012			2011
	Risk-free interest rate(1)	0.2	%		0.2	%		0.5	%
	Dividend yield	—	%		—	%		—	%
	Volatility(2)	35.1	%		38.5	%		40.2	%
	Expected life(3)	0.5 - 2 yrs			0.5 - 2 yrs			0.5 - 2 yrs
	_______________________________________________________________________________
	-1	The risk-free interest rate for both stock options and the ESPP is based on the zero-coupon U.S. Treasury rate curve in effect at the time of the option grant or at the beginning of the ESPP offering period.
	-2	Expected volatility for both stock options and the ESPP reflects a combination of historical and market-based implied volatility consistent with ASC 718 and SEC Staff Accounting Bulletin 107. We determined that the combination of historical and market-based implied volatility provides a more accurate reflection of our market conditions and is more representative of future stock price trends than employing solely historical volatility.
	-3	Represents the period of time that options granted are expected to be outstanding, which is derived from historical data on employee exercise and post-vesting employment termination behavior.
Schedule of stock options activity	'
	A summary of option activity under the 2009 Plan for the years ended December 31, 2013, 2012 and 2011 is presented below:
	Options:	Number of Shares			Weighted Average
					Exercise Price
		(in thousands)
	Outstanding at December 31, 2010	4,740			$	12.86
	Granted	494			$	14.57
	Exercised	(413	)		$	8.3
	Expired	(86	)		$	13.59
	Forfeited	(42	)		$	20.76
	Outstanding at December 31, 2011	4,693			$	13.36
	Granted	645			$	14.85
	Exercised	(669	)		$	8.65
	Expired	(84	)		$	14.02
	Forfeited	(115	)		$	21.44
	Outstanding at December 31, 2012	4,470			$	14.06
	Granted	502			$	20.25
	Exercised	(1,686	)		$	12.53
	Expired	(56	)		$	15.66
	Forfeited	(87	)		$	14.68
	Outstanding at December 31, 2013	3,143			$	15.82
	Vested and expected to vest at December 31, 2013	3,114			$	15.79
	Exercisable at December 31, 2013	2,078			$	15.11
Schedule of outstanding and exercisable options by exercise price range	'
	The ranges of outstanding and exercisable options for equity share-based payment awards as of December 31, 2013 were as follows:
	Range of Exercise Prices	Number			Weighted				Number			Weighted
		Outstanding			Average Exercise				Exercisable			Average Exercise
					Price of							Price of
					Outstanding							Exercisable
					Options							Options
		(in thousands)							(in thousands)
	$6.40 - $10.41	332			$	8.71			332			$	8.71
	$10.58 - $10.75	384			$	10.65			384			$	10.65
	$11.27 - $13.53	347			$	12.84			291			$	12.77
	$13.67 - $14.10	358			$	13.86			143			$	13.94
	$14.16 - $15.04	364			$	14.58			167			$	14.67
	$15.06 - $17.29	382			$	16.79			106			$	16.51
	$17.49 - $20.95	434			$	19.84			369			$	20.12
	$21.07 - $23.19	330			$	22.52			104			$	21.5
	$23.41 - $26.99	136			$	24.61			106			$	24.76
	$29.16 - $29.16	76			$	29.16			76			$	29.16
	$6.40 - $29.16	3,143			$	15.82			2,078			$	15.11
Schedule of restricted stock and restricted stock units activity	'
	A summary of activity of restricted stock and restricted stock units ("RSUs") granted under the 2009 Plan as of December 31, 2013 is presented below:
		Shares of				Weighted-Average Grant			Restricted Stock Units			Weighted-Average Grant
		Restricted Stock				Date Fair Value Per Share						Date Fair Value
		(in thousands)							(in thousands)
	Nonvested at December 31, 2010	77				$	12.91		308			$	12.98
	Granted	68				$	14.71		145			$	14.39
	Vested	(77		)		$	12.91		(152	)		$	14.26
	Forfeited	—				—			(14	)		$	12.82
	Nonvested at December 31, 2011	68				$	14.71		287			$	13.03
	Granted	67				$	14.19		274			$	14.58
	Vested	(78		)		$	14.64		(153	)		$	12.9
	Forfeited	—				—			(19	)		$	14.55
	Nonvested at December 31, 2012	58				$	14.19		389			$	14.09
	Granted	$	55			$	18.2		190			19.87
	Vested	$	(61	)		$	14.23		(195	)		14.31
	Forfeited	—				—			(22	)		14.08
	Nonvested at December 31, 2013	$	52			$	18.43		362			17.15
PSU 2011 percentile placement	'
	The following table shows the percent of PSUs granted in 2011 and eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return		% of PSUs Eligible for Time-
			Based Vesting
	Below the 35th percentile		—%
	At least the 35th percentile, but below the 50th percentile		50%
	At least the 50th percentile, but below the 65th percentile		100%
	At least the 65th percentile, but below the 75th percentile (1)		110% to 119%
	At or above the 75th percentile		120%
PSU 2012 percentile placement	'
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
Schedule of performance-based units activity	'
	A summary of activity of the PSUs for the years ended December 31, 2013 and 2012 is presented below:
	Performance-based Stock Units	Number of Units			Weighted-
					Average
					Grant Date
					Fair Value Per
					Unit
		(in thousands)
	Non-vested, December 31, 2011	100			$	11.15
	Granted	135			$	10.94
	Vested	(60	)		$	11.15
	Forfeited	—			$	—
	Non-vested, December 31, 2012	175			$	11
	Granted	142			$	14.68
	Vested	(57	)		$	11.15
	Forfeited	(35	)		$	10.93
	Non-vested, December 31, 2013	225			$	13.32

Segments_Tables

Segments (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting Information [Line Items]	'
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
	For the years ended December 31, 2013, 2012 and 2011 the contributions of our segments to net revenues and income from operations, and the reconciliation to total net income, were as follows (amounts in thousands):
		December 31,									December 31,									December 31,
		2013									2012									2011
		Acute Care			Non-Acute Care			Total			Acute Care			Non-Acute Care (1)			Total			Acute Care			Total
	Net revenues from external customers	$	284,666		$	95,919		$	380,585		$	260,160		$	53,867		$	314,027		$	245,535		$	245,535
	Cost of revenues	122,816			54,370			177,186			111,599			31,840			143,439			109,751			109,751
	Gross profit	$	161,850		$	41,549		$	203,399		$	148,561		$	22,027		$	170,588		$	135,784		$	135,784
	Gross margin %	56.9		%	43.3		%	53.4		%	57.1		%	40.9		%	54.3		%	55.3		%	55.3		%
	Operating expenses	131,811			36,289			168,100			127,467			15,995			143,462			119,562			119,562
	Income from operations	$	30,039		$	5,260		$	35,299		$	21,094		$	6,032		$	27,126		$	16,222		$	16,222
	Operating margin %	10.6		%	5.5		%	9.3		%	8.1		%	11.2		%	8.6		%	6.6		%	6.6		%
	Interest and other income (expense), net							(270		)							(51		)				(133		)
	Income before provision for income taxes							35,029									27,075						16,089
	Provision for income taxes							11,050									10,897						5,700
	Net income							$	23,979								$	16,178					$	10,389
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the closing date of acquisition.
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	At December 31, 2013, 2012, and 2011 segment assets, depreciation and amortization, and capital expenditures were as follows (amounts in thousands):
		December 31,									December 31,									December 31,
		2013									2012									2011
		Acute Care			Non-Acute Care (1)			Total			Acute Care			Non-Acute Care (1)			Total			Acute Care			Total
	Segment Assets	$	263,154		$	229,347		$	492,501		$	235,186		$	206,633		$	441,819		$	363,849		$	363,849
	Depreciation/Amortization	$	11,236		$	7,129		$	18,365		$	9,017		$	4,308		13,325			7,983			7,983
	Capital Expenditures	$	4,392		$	7,943		$	12,335		$	13,234		$	1,953		$	15,187		$	8,685		$	8,685
	(1) Non-Acute Care segment includes MTS results from May 21, 2012, the date of acquisition.

Business_Acquisition_Details

Business Acquisition (Details) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	21-May-13	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	20-May-12
Business Acquisition [Line Items]	'	'	'	'	'	'
Document Period End Date	'	'	31-Dec-13	'	'	'
Business Acquisition, Cash Received Through Release of Escrow Funds	'	$300,000	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]	'	'	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Assets, Inventory	'	'	'	'	'	11,726,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	'	'	'	'	'	2,894,000
Business Acquisition, Purchase Price Allocation, Current Assets	'	'	'	'	'	24,023,000
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment	'	'	'	'	'	9,807,000
Business Acquisition, Purchase Price Allocation, Intangible Assets Other than Goodwill	'	'	'	'	'	83,900,000
Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets	'	'	'	'	'	308,000
Business Acquisition, Purchase Price Allocation, Assets Acquired	'	'	'	'	'	200,838,000
Business Acquisition, Purchase Price Allocation, Current Liabilities	'	'	'	'	'	-7,917,000
Business Acquisition, Purchase Price Allocation, Deferred Tax Liabilities, Noncurrent	'	'	'	'	'	-33,386,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	'	'	'	'	'	1,223,000
Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net	'	'	'	'	'	158,312,000
Cash including restricted cash	'	'	'	'	'	2,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	'	'	'	'	'	7,403,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	'	'	24,019,000	16,308,000	10,390,000	'
Goodwill	'	111,407,000	111,343,000	111,407,000	'	82,800,000
Business Combination, Consideration Transferred	158,312,000	'	'	'	'	'
MTS-Medication Technologies [Member]	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'
Business acquisition cash paid at closing	'	'	'	'	'	158,312,000
business acquisition sellers escrow account	'	'	'	'	'	13,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]	'	'	'	'	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'	'25 years 1 month 21 days	'	'	'
Business Combination, Consideration Transferred	$158,312,000	'	'	'	'	'
Minimum [Member] | MTS-Medication Technologies [Member]	'	'	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]	'	'	'	'	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'	'12 years	'	'	'
Maximum [Member] | MTS-Medication Technologies [Member]	'	'	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]	'	'	'	'	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'	'	'30 years	'	'	'

Business_Acquisition_Bus_acqui

Business Acquisition Bus acquisition - Table of acquired Intangibles (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Business Combination, Acquisition Related Costs	'	$3,200,000	'
Revenues	380,585,000	314,027,000	245,535,000
Net Income (Loss) Available to Common Stockholders, Basic	23,979,000	16,178,000	10,389,000
Trade Names [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'	'
Trade Names [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'12 years	'	'
Customer Relationships [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'	'
Customer Relationships [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'	'
Acquired Technology [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'	'
Acquired Technology [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'	'
MTS-Medication Technologies [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Acquired Finite-lived Intangible Asset, Amount	'	83,900,000	'
Expected amortization of acquired intangibles first year	'	3,604,000	'
Weighted average life of intangibles	'25 years 1 month 21 days	'	'
Revenues	'	47,200,000	'
MTS-Medication Technologies [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Weighted average life of intangibles	'12 years	'	'
MTS-Medication Technologies [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Weighted average life of intangibles	'30 years	'	'
MTS-Medication Technologies [Member] | Trade Names [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Acquired Finite-lived Intangible Asset, Amount	'	6,800,000	'
Finite-Lived Intangible Asset, Useful Life	'12 years	'	'
Expected amortization of acquired intangibles first year	'	567,000	'
MTS-Medication Technologies [Member] | Customer Relationships [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Acquired Finite-lived Intangible Asset, Amount	'	50,500,000	'
Expected amortization of acquired intangibles first year	'	1,707,000	'
MTS-Medication Technologies [Member] | Customer Relationships [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'28 years	'	'
MTS-Medication Technologies [Member] | Customer Relationships [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'	'
MTS-Medication Technologies [Member] | Acquired Technology [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Acquired Finite-lived Intangible Asset, Amount	'	26,600,000	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'	'
Expected amortization of acquired intangibles first year	'	1,330,000	'
Non-acute care solutions [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Revenues	95,919,000	53,867,000	'
Non-acute care solutions [Member] | MTS-Medication Technologies [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Net Income (Loss) Available to Common Stockholders, Basic	'	$2,900,000	'

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies Marketable Securities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Trading Securities	'	$0	'	'
Held-to-maturity Securities, Fair Value	'	0	'	'
Cash and cash equivalents	104,531,000	62,313,000	191,762,000	175,635,000
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents	65,708,000	38,892,000	'	'
Cash and Cash Equivalents, Fair Value Disclosure	65,708,000	38,891,000	'	'
Cash and Cash Equivalents [Member] | Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$65,708,000	$38,891,000	'	'

Business_Acquisition_Acquiree_

Business Acquisition Acquiree operating results to date since acquisition (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'
Revenues	$380,585	$314,027	$245,535
Net income	23,979	16,178	10,389
MTS-Medication Technologies [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Revenues	'	47,200	'
Non-acute care solutions [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Revenues	95,919	53,867	'
Non-acute care solutions [Member] | MTS-Medication Technologies [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Net income	'	$2,900	'

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies Risks - Concentration Revenue, Accounts Receivable and Dependence on Suppliers (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	customer	customer
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Cash Flows Between Transferor and Transferee, Proceeds from New Transfers	$41,300,000	'	$46,900,000
Percentage of Product Revenue from Foreign Countries	11.20%	7.50%	2.00%
customers with 10% revenue concentration	0	0	'
customers with 10 % accts rec concentration	0	0	'
Trading Securities	'	0	'
Held-to-maturity Securities, Fair Value	'	0	'
Purchases from significant supplier	29,200,000	23,800,000	21,100,000
Lease Agreements [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Cash Flows Between Transferor and Transferee, Proceeds from New Transfers	'	60,900,000	'
Lease Transfers In Ending Accounts Receivable	$100,000	$700,000	$200,000
Equipment [Member] | Minimum [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies Property and Equipment and Software Development Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$75,682,000	$67,209,000	'
Capitalized Computer Software, Additions	7,800,000	5,000,000	'
Capitalized Computer Software, Amortization	3,200,000	2,300,000	1,600,000
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	7,394,000	6,992,000	'
Furniture and Fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	5,260,000	5,126,000	'
Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	40,180,000	32,528,000	'
Equipment [Member] | Minimum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'
Internal Use Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$4,800,000	$5,400,000	'

Business_Acquisition_Bus_Acq_t

Business Acquisition Bus Acq - tranasaction costs expense in period (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012
Business Acquisition [Abstract]	'
Business Combination, Acquisition Related Costs	$3.20

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies Shipping and Advertising costs (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'
Shipping, Handling and Transportation Costs	$6.10	$4.10	$2.70
Advertising Expense	$0.50	$0.50	$0.90

Net_Income_Per_Share_Details

Net Income Per Share (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Earnings Per Share, Basic	$0.69	$0.49	$0.31
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	850,133	2,149,044	1,833,574
Earnings Per Share, Basic [Abstract]	'	'	'
Net income	$23,979	$16,178	$10,389
Weighted Average Number of Shares Outstanding, Basic	34,736,000	33,307,000	33,123,000
Earnings Per Share, Diluted [Abstract]	'	'	'
Net income	$23,979	$16,178	$10,389
Weighted Average Number of Shares Outstanding, Basic	34,736,000	33,307,000	33,123,000
Incremental Common Shares Attributable to Share-based Payment Arrangements	1,041,000	906,000	980,000
Weighted Average Number of Shares Outstanding, Diluted	35,777,000	34,213,000	34,103,000
Net income per share - diluted	$0.67	$0.47	$0.30

Cash_and_Cash_Equivalents_Shor2

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments marketable securities - gain or loss (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Money Market Fund - daily traded value	$1	'	'	'
Cash and cash equivalents, Amortized Cost	104,531,000	62,313,000	191,762,000	175,635,000
Cash, cash equiv and S-T-I: Amortized cost	104,531,000	62,314,000	'	'
Cash, cash equiv and S-T-I: Gross unrealized gains	0	0	'	'
Cash, cash equiv and S-T-I: Gross unrealized losses	0	1,000	'	'
Cash, Cash Equivalents, and Short-term Investments	104,531,000	62,313,000	'	'
Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	38,823,000	23,422,000	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	38,823,000	23,422,000	'	'
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	65,708,000	38,892,000	'	'
Cash and cash equivalents - gross unrealized gain	'	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	1,000	'	'
Cash and Cash Equivalents, Fair Value Disclosure	65,708,000	38,891,000	'	'
Cash and Cash Equivalents [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash, Cash Equivalents, and Short-term Investments	104,531,000	62,313,000	'	'
Cash and Cash Equivalents [Member] | Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	38,823,000	23,422,000	'	'
Cash and Cash Equivalents [Member] | Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$65,708,000	$38,891,000	'	'

Cash_and_Cash_Equivalents_Shor3

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments avail for sale securities levels 1-2-3 table (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	$104,531	$62,313
Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	65,708	38,891
Fair Value, Measurements, Recurring [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	65,708	38,891
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	65,708	38,891
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	65,708	38,891
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	65,708	38,891
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash, Cash Equivalents, and Short-term Investments	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	'	$0

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$10,765	$9,994
Work in process	534	385
Finished goods	20,158	16,524
Total	$31,457	$26,903

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$75,682,000	$67,209,000	'
Accumulated depreciation and amortization	-40,428,000	-33,102,000	'
Property and equipment, net	35,254,000	34,107,000	'
Depreciation expense	10,900,000	8,000,000	5,700,000
Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	40,180,000	32,528,000	'
Furniture and Fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	5,260,000	5,126,000	'
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	7,394,000	6,992,000	'
Software and Software Development Costs [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	20,199,000	'	'
Purchased Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	'	19,870,000	'
Construction in Progress [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$2,649,000	$2,693,000	'

Net_Investment_in_SalesType_Le2

Net Investment in Sales-Type Leases sales type lease - from min payments to non current investment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Capital Leased Assets [Line Items]	'	'
Net minimum lease payments to be received	$18,172,000	$19,665,000
Less unearned interest income portion	1,455,000	1,205,000
Net investment in sales-type leases	16,717,000	18,460,000
Less current portion	5,232,000	5,232,000
Non-current net investment in sales-type leases (2)	11,485,000	13,228,000
Allowance for Notes, Loans and Financing Receivable, Current	100,000	500,000
Allowance for Notes, Loans and Financing Receivable, Noncurrent	$100,000	$100,000

Net_Investment_in_SalesType_Le3

Net Investment in Sales-Type Leases (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Net Investment in Sales-Type Leases [Abstract]	'
Contractual Term of Sales Type Leases	'5 years
2014	$5,851
2015	4,857
2016	3,618
2017	2,710
2018	1,136
Capital Leases, Future Minimum Payments Receivable	$18,172

Net_Investment_in_SalesType_Le4

Net Investment in Sales-Type Leases Credit loss balances by evaluation method for impairment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Financing Receivable, Allowance for Credit Losses [Line Items]	'	'
Financing Receivable, Allowance for Credit Losses, Individually Evaluated for Impairment	$0	$489
Financing Receivable Gross - individually evaluated for impairment	0	489
Financing Receivable, Individually Evaluated for Impairment	0	0
Financing Receivable, Allowance for Credit Losses, Collectively Evaluated for Impairment	167	118
Financing Receivable Gross - collectively evalauated for impairment	16,884	18,578
Financing Receivable, Collectively Evaluated for Impairment	16,717	18,460
Financing Receivable, Allowance for Credit Losses	167	607
Financing Receivable, Gross	16,884	19,067
Financing Receivable, Net	$16,717	$18,460

Net_Investment_in_SalesType_Le5

Net Investment in Sales-Type Leases allowance credit loss rollforward (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Financing Receivable, Allowance for Credit Losses [Roll Forward]	'
Allowance for credit losses, beginning of period	$607
Current period provision (reversal)	49
Financing Receivable, Allowance for Credit Losses, Write-downs	-413
Recoveries of amounts previously charged off	-76
Allowance for credit losses, end of period	$167

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Goodwill rollforward by segment (details) (USD $)	12 Months Ended
	Dec. 31, 2013	20-May-12
Goodwill [Line Items]	'	'
Goodwill, Purchase Accounting Adjustments	$100,000	'
Goodwill, Period Increase (Decrease)	-64,000	'
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	111,407,000	82,800,000
Goodwill, Ending balance	111,343,000	82,800,000
Acute care systems [Member]	'	'
Goodwill [Line Items]	'	'
Goodwill, Period Increase (Decrease)	0	'
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	28,543,000	'
Goodwill, Ending balance	28,543,000	'
Non-acute care solutions [Member]	'	'
Goodwill [Line Items]	'	'
Goodwill, Period Increase (Decrease)	-64,000	'
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	82,864,000	'
Goodwill, Ending balance	$82,800,000	'
acquired technology [Member] | Minimum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'
acquired technology [Member] | Maximum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'
Patents [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'
Trade Names [Member] | Minimum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Trade Names [Member] | Maximum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'12 years	'
Customer Relationships [Member] | Minimum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'
Customer Relationships [Member] | Maximum [Member]	'	'
Goodwill [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Finite life intangibles Gross and Net at balance sheet dates (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	$90,753,000	$90,477,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	9,151,000	4,927,000	'
Total Finite-Lived Intangibles	81,602,000	85,550,000	'
Capitalized Third Party Costs Related to Internally Developed Intangibles	400,000	400,000	200,000
Amortization of Intangible Assets	4,300,000	2,900,000	700,000
Customer Relationships [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	54,730,000	54,730,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	5,236,000	3,081,000	'
Total Finite-Lived Intangibles	49,494,000	51,649,000	'
Customer Relationships [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'	'
Customer Relationships [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'30 years	'	'
Acquired Technology [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	27,580,000	27,580,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	2,598,000	1,128,000	'
Total Finite-Lived Intangibles	24,982,000	26,452,000	'
Acquired Technology [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'	'
Acquired Technology [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'	'
Patents [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	1,493,000	1,217,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	254,000	259,000	'
Total Finite-Lived Intangibles	1,239,000	958,000	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'	'
Trade Names [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	6,890,000	6,890,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	1,003,000	414,000	'
Total Finite-Lived Intangibles	5,887,000	6,476,000	'
Trade Names [Member] | Minimum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'	'
Trade Names [Member] | Maximum [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'12 years	'	'
Noncompete Agreements [Member]	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Assets, Gross	60,000	60,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	60,000	45,000	'
Total Finite-Lived Intangibles	$0	$15,000	'

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Future amortizaion of intangibles (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
2013	$4,229	'
2014	4,204	'
2015	3,854	'
2016	3,818	'
2017	3,711	'
Thereafter	61,786	'
Total Finite-Lived Intangibles	$81,602	$85,550

Other_Assets_Details

Other Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'	'
Capitalized Computer Software, Net	$13,660	$11,037
technologylicenseasset	2,350	2,800
Deposits Assets, Noncurrent	'	694
Non-current deferred service billings receviable	682	'
Other Assets, Miscellaneous, Noncurrent	1,245	1,247
Other Assets, Noncurrent	17,937	15,778
Capitalized Computer Software, Accumulated Amortization	$10,547	$7,329

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]	'	'
Rebates and lease buyouts	$1,699	$3,179
Advance payments from customers	4,971	2,829
Accrued Group Purchasing Organization (GPO) fees	2,324	2,278
technologylicensepurchaseobigationcurrent	1,500	1,750
Taxes payable	1,664	555
Other	1,588	1,397
Total	$13,746	$11,988

Deferred_Gross_Profit_Details

Deferred Gross Profit (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Gross Profit [Abstract]	'	'
Sales of Medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$29,040	$30,138
Cost of revenues, excluding installation costs	-9,083	-9,366
Deferred gross profit	$19,957	$20,772

Commitments_Details

Commitments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'
2014	$5,787
2015	5,476
2016	5,150
2017	4,468
2018	4,298
Thereafter	16,601
Total	$41,780

Commitments_rented_properties_

Commitments rented properties data (Details) (USD $)	12 Months Ended				53 Months Ended	12 Months Ended	53 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jun. 30, 2012	Dec. 31, 2013	Jun. 30, 2012	Dec. 31, 2013	Sep. 30, 2012	Dec. 31, 2013
				Lease- Mountain View, CA 590 Middlefield road [Member]	Lease- Mountain View, CA 590 Middlefield road [Member]	Lease - Milpitas, CA 735 Sycamore Drive [Member]	Lease - Milpitas, CA 735 Sycamore Drive [Member]	Lease - St. Petersburg, FL 2003 gaudy Bldvd. North [Member]	lease - Leeds, United Kingdom [Member]	lease - Leeds, United Kingdom [Member]
					sqft		sqft	sqft	sqft
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense	$8.10	$5.70	$3.30	'	'	'	'	'	'	'
Operating Leases, Income Statement, Sublease Revenue	'	'	0.5	'	'	'	'	'	'	'
property subject to operating lease, net rentable area	'	'	'	'	100,000	'	46,000	132,500	16,500	'
property subject to operating lease term duration	'	'	'	'	'10 years	'	'60 months	'	'	'
Operating Leases, Rent Expense, Minimum Rentals	'	'	'	'	$40	'	$1.80	$3.90	'	$1.20
property subject to lease, 1st extension term duration	'	'	'	'	'	'	'	'12 years	'	'10 years
Lease Expiration Date	'	'	'	'	'	'	'	'	'	8-Jun-21
property subject to lease, 1st extension term duration	'	'	'	'60 months	'	'60 months	'	'60 months	'	'0
Property subject to operating lease, 2nd extension term duration	'	'	'	'60 months	'	'	'	'60 months	'	'

Commitments_supplier_obligatio

Commitments supplier obligation (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Commitments [Abstract]	'
Purchase Commitment, Remaining Minimum Amount Committed	$7.40

Contingencies_Details

Contingencies (Details)	12 Months Ended
	Dec. 31, 2013
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'30 days
Medication Packaging Systems [Member]	'
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'6 months

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]	'	'	'
Domestic	$34,678,000	$25,794,000	$16,177,000
Foreign	351,000	1,281,000	-88,000
Income before provision for income taxes	35,029,000	27,075,000	16,089,000
Current:	'	'	'
Federal	8,218,000	7,181,000	4,285,000
State	1,621,000	1,006,000	896,000
Foreign	447,000	154,000	-70,000
Total current	10,286,000	8,341,000	5,111,000
Deferred:	'	'	'
Federal	1,287,000	2,169,000	1,116,000
State	-263,000	651,000	-527,000
Foreign	-260,000	-264,000	0
Total deferred	764,000	2,556,000	589,000
Provision for income taxes	11,050,000	10,897,000	5,700,000
Income Tax Reconciliation:	'	'	'
U.S. federal tax provision at statutory rate	12,260,000	9,476,000	5,631,000
State taxes	883,000	1,077,000	240,000
Non-deductible expenses	297,000	530,000	481,000
Acquisition costs	0	431,000	0
Share-based compensation expense	407,000	403,000	443,000
Research tax credits	-1,430,000	0	-755,000
Domestic production deduction	-816,000	-601,000	-271,000
Other	-551,000	-419,000	-69,000
Provision for income taxes	11,050,000	10,897,000	5,700,000
Components of Deferred Tax Assets and Liabilities:	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards	3,160,000	2,990,000	'
Deferred Tax Assets, Inventory related items	2,947,000	2,900,000	'
Deferred Tax Assets, Deferred revenue	11,074,000	11,497,000	'
Deferred Tax Assets, Stock compensation	7,447,000	9,331,000	'
Deferred Tax Assets, Loss carry forwards	64,000	53,000	'
Deferred Tax Assets, Other net	5,000	69,000	'
Deferred Tax Assets, Gross	24,697,000	26,840,000	'
Deferred Tax Assets, Valuation Allowance	-39,000	-39,000	'
Deferred Tax Assets, Net of Valuation Allowance	24,658,000	26,801,000	'
Deferred Tax Liabilities, Reserves and accruals	-353,000	-573,000	'
Deferred Tax Liabilities, Depreciation and amortization	-38,681,000	-39,840,000	'
Deferred Tax Liabilities, Gross	-39,034,000	-40,413,000	'
Deferred Tax Liabilities, Net	14,376,000	13,612,000	'
Reconciliation of Unrecognized Tax Benefits [Roll Forward]	'	'	'
Unrecognized Tax Benefits	6,915,000	5,796,000	5,431,000
Increases related to tax positions taken during a prior period	406,000	43,000	'
Increases related to tax positions related to MTS	'	1,066,000	'
Decreases related to tax positions taken during the prior period	-79,000	'	-88,000
Increases related to tax positions taken during the current period	764,000	422,000	453,000
Decreases related to settlements	'	-33,000	'
Decreases related to expiration of statute of limitations	-32,000	-379,000	'
Unrecognized Tax Benefits	7,974,000	6,915,000	5,796,000
Tax effected amounts of gross unrealized net operating loss and business tax credit carry forwards excluded under ASC 718	2,600,000	'	'
Undistributed Earnings of Foreign Subsidiaries	2,800,000	'	'
Unrecognized tax benefits that would affect tax expense	7,000,000	'	'
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries	1,100,000	'	'
State and Local Jurisdiction [Member]	'	'	'
Reconciliation of Unrecognized Tax Benefits [Roll Forward]	'	'	'
Operating Loss Carryforwards	2,200,000	'	'
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]	'	'	'
Reconciliation of Unrecognized Tax Benefits [Roll Forward]	'	'	'
Tax Credit Carryforward, Amount	7,200,000	'	'
Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]	'	'	'
Reconciliation of Unrecognized Tax Benefits [Roll Forward]	'	'	'
Tax Credit Carryforward, Amount	$1,500,000	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	11 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Stock [Line Items]	'	'	'	'
Payments for Repurchase of Common Stock	'	$20,962	$12,363	$12,573
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings	'	103,229	79,968	43,174
2008 Repurchase Program [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Stock Repurchase Program, Authorized Amount	'	90,000	'	'
Treasury Stock, Shares, Acquired	'	'	898,168	889,511
Treasury Stock Acquired, Average Cost Per Share	$15	'	$13.76	$14.13
Shares Repurchased to date	5,853,975	'	'	'
2012 Repurchase Program [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Stock Repurchase Program, Authorized Amount	'	50,000	'	'
Payments for Repurchase of Common Stock	'	20,962	'	'
Treasury Stock, Shares, Acquired	'	885,000	'	'
Treasury Stock Acquired, Average Cost Per Share	'	$23.70	'	'
Stock Repurchase Program, Remaining Authorized Repurchase Amount	'	$29,064	'	'

Stock_Option_Plans_and_ShareBa2

Stock Option Plans and Share-Based Compensation-Narrative (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

21-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

19-May-09

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2009

Dec. 31, 2013

Equity Option [Member]

Employee Stock Option [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Option [Member]

Maximum [Member]

VestingInstallment

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

Number of shares not available for grant for each share granted

'

'

'

'

'

'

1.4

1.4

0

'

'

'

'

'

Number of additional shares authorized

'

'

'

'

'

2,500,000

2,600,000

'

'

'

'

'

2,622,426

'

Award vesting period

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Monthly Vesting Installments After Initial Cliff

'

'

'

'

'

'

'

'

'

'

36

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Maximum annual contribution per employee, percent

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

Maximum annual contribution per employee

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

Purchase price of stock, percent

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

Number of shares available for grant

3,060,505

'

'

'

'

'

'

'

'

'

'

1,097,998

'

'

Stock Issued During Period, Shares, Employee Stock Purchase Plans

'

'

'

'

'

'

'

'

'

'

'

450,713

'

'

Stock Issued Since Plan Inception, Shares Employee Stock Purchase Plans

'

'

'

'

'

'

'

'

'

'

'

4,233,557

'

'

Total compensation cost not yet recognized

'

'

'

'

7,100,000

'

'

'

'

'

'

1,176,000

'

'

Period for recognition

'

'

'

'2 years 8 months 12 days

'

'

'2 years 8 months 12 days

'

'

'

'

'7 months 18 days

'

'

Maximum employee subscription rate contribution per employee, percent

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Employer matching contribution, percent

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum annual contribution per employee

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost recognized

1,100,000

800,000

600,000

'

'

'

'

'

'

'

'

'

'

'

Total compensation cost not yet recognized

'

'

'

'

'

'

$7,100,000

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa3

Stock Option Plans and Share-Based Compensation Stock expense by P&L caption (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$11,151	$9,214	$9,499
Increase to additional paid in capital from share-based compensation	2,400	2,600	2,900
Cost of revenues [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	1,241	1,011	1,398
Research and development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	1,359	889	1,269
Selling, general and administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$8,551	$7,314	$6,832

Stock_Option_Plans_and_ShareBa4

Stock Option Plans and Share-Based Compensation-Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	1.20%	0.90%	1.60%
Dividend yield	0.00%	0.00%	0.00%
Volatility	43.10%	45.80%	48.50%
Employee Stock Purchase Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	0.20%	0.20%	0.50%
Dividend yield	0.00%	0.00%	0.00%
Volatility	35.10%	38.50%	40.20%
Employee Stock Purchase Plan [Member] | Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term	'	'6 months	'6 months
Employee Stock Purchase Plan [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term	'	'2 years	'2 years

Stock_Option_Plans_and_ShareBa5

Stock Option Plans and Share-Based Compensation Stock option rollforward YTD (Details) (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'5 years 3 months 18 days	'	'
Number of Shares [Roll Forward]	'	'	'
Beginning balance	4,470	4,693	4,740
Granted	502	645	494
Exercised	-1,686	-669	-413
Expired	-56	-84	-86
Forfeited	-87	-115	-42
Ending balance	3,143	4,470	4,693
Weighted Average Exercise Price [Roll Forward]	'	'	'
Beginning balance	$14.06	$13.36	$12.86
Granted	$20.25	$14.85	$14.57
Exercised	$12.53	$8.65	$8.30
Expired	$15.66	$14.02	$13.59
Forfeited	$14.68	$21.44	$20.76
Ending balance	$15.82	$14.06	$13.36
Additional Disclosures [Abstract]	'	'	'
Vested and expected to vest	3,114	'	'
Number Exercisable	2,078	'	'
Vested and expected to vest	$15.79	'	'
Weighted Average Exercise Price of Exercisable Options	$15.11	'	'
Options outstanding, intrinsic value	$30,800,000	'	'
Vested and expected to vest, weighted average remaining contratual term	'5 years 7 months	'5 years 7 months 20 days	'
Options vested and expected to vest, aggregate intrinsic value	30,600,000	'	'
Options exercisable, weighted average remaining contractual term	'4 years 1 month	'	'
Options exercisable, intrinsic value	22,000,000	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,143	4,470	4,693
Weighted Average Exercise Price of Outstanding Options	$15.82	$14.06	$13.36
Number Exercisable	2,078	'	'
Weighted Average Exercise Price of Exercisable Options	$15.11	'	'
Exercise price range, lower range limit	$2.70	'	'
Exercise price range, upper range limit	$29.16	'	'
Grants in period, weighted average grant date fair value	$8.09	$6.13	$6.47
Exercises in period, total intrinsic value	14,000,000	2,800,000	2,900,000
$2.70 - $9.25 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	332	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$8.71	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	332	'	'
Weighted Average Exercise Price of Exercisable Options	$8.71	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	332	'	'
Weighted Average Exercise Price of Outstanding Options	$8.71	'	'
Number Exercisable	332	'	'
Weighted Average Exercise Price of Exercisable Options	$8.71	'	'
Exercise price range, lower range limit	$2.70	'	'
Exercise price range, upper range limit	$9.25	'	'
$9.34 - $10.58 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	384	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$10.65	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	384	'	'
Weighted Average Exercise Price of Exercisable Options	$10.65	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	384	'	'
Weighted Average Exercise Price of Outstanding Options	$10.65	'	'
Number Exercisable	384	'	'
Weighted Average Exercise Price of Exercisable Options	$10.65	'	'
Exercise price range, lower range limit	$9.34	'	'
Exercise price range, upper range limit	$10.58	'	'
$10.60 - $11.58 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	347	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$12.84	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	291	'	'
Weighted Average Exercise Price of Exercisable Options	$12.77	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	347	'	'
Weighted Average Exercise Price of Outstanding Options	$12.84	'	'
Number Exercisable	291	'	'
Weighted Average Exercise Price of Exercisable Options	$12.77	'	'
Exercise price range, lower range limit	$10.60	'	'
Exercise price range, upper range limit	$11.58	'	'
$11.66 - $13.16 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	358	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$13.86	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	143	'	'
Weighted Average Exercise Price of Exercisable Options	$13.94	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	358	'	'
Weighted Average Exercise Price of Outstanding Options	$13.86	'	'
Number Exercisable	143	'	'
Weighted Average Exercise Price of Exercisable Options	$13.94	'	'
Exercise price range, lower range limit	$11.66	'	'
Exercise price range, upper range limit	$13.16	'	'
$13.33 - $13.74 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	364	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$14.58	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	167	'	'
Weighted Average Exercise Price of Exercisable Options	$14.67	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	364	'	'
Weighted Average Exercise Price of Outstanding Options	$14.58	'	'
Number Exercisable	167	'	'
Weighted Average Exercise Price of Exercisable Options	$14.67	'	'
Exercise price range, lower range limit	$13.33	'	'
Exercise price range, upper range limit	$13.74	'	'
$13.88 - $14.38 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	382	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$16.79	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	106	'	'
Weighted Average Exercise Price of Exercisable Options	$16.51	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	382	'	'
Weighted Average Exercise Price of Outstanding Options	$16.79	'	'
Number Exercisable	106	'	'
Weighted Average Exercise Price of Exercisable Options	$16.51	'	'
Exercise price range, lower range limit	$13.88	'	'
Exercise price range, upper range limit	$14.38	'	'
$14.42 - $16.70 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	434	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$19.84	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	369	'	'
Weighted Average Exercise Price of Exercisable Options	$20.12	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	434	'	'
Weighted Average Exercise Price of Outstanding Options	$19.84	'	'
Number Exercisable	369	'	'
Weighted Average Exercise Price of Exercisable Options	$20.12	'	'
Exercise price range, lower range limit	$14.42	'	'
Exercise price range, upper range limit	$16.70	'	'
$16.73 - $20.95 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	330	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$22.52	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	104	'	'
Weighted Average Exercise Price of Exercisable Options	$21.50	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	330	'	'
Weighted Average Exercise Price of Outstanding Options	$22.52	'	'
Number Exercisable	104	'	'
Weighted Average Exercise Price of Exercisable Options	$21.50	'	'
Exercise price range, lower range limit	$16.73	'	'
Exercise price range, upper range limit	$20.95	'	'
$21.07 - $26.99 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	136	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$24.61	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	106	'	'
Weighted Average Exercise Price of Exercisable Options	$24.76	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	136	'	'
Weighted Average Exercise Price of Outstanding Options	$24.61	'	'
Number Exercisable	106	'	'
Weighted Average Exercise Price of Exercisable Options	$24.76	'	'
Exercise price range, lower range limit	$21.07	'	'
Exercise price range, upper range limit	$26.99	'	'
$29.16 - $29.16 [Member]	'	'	'
Number of Shares [Roll Forward]	'	'	'
Ending balance	76	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Ending balance	$29.16	'	'
Additional Disclosures [Abstract]	'	'	'
Number Exercisable	76	'	'
Weighted Average Exercise Price of Exercisable Options	$29.16	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	76	'	'
Weighted Average Exercise Price of Outstanding Options	$29.16	'	'
Number Exercisable	76	'	'
Weighted Average Exercise Price of Exercisable Options	$29.16	'	'
Exercise price range, lower range limit	$29.16	'	'
Exercise price range, upper range limit	$29.16	'	'
Stock Options [Member]	'	'	'
Share-based Compensation, Exercise Price Range [Abstract]	'	'	'
Total compensation cost not yet recognized	$7,100,000	'	'

Stock_Option_Plans_and_ShareBa6

Stock Option Plans and Share-Based Compensation Restricted Stock Awards and RSUs rollforward (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Range Two [Member]

Range Three [Member]

Range Four [Member]

Range Five [Member]

Range Six [Member]

Range Seven [Member]

Range Eight [Member]

Range Nine [Member]

Range Ten [Member]

Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,143,000

4,470,000

4,693,000

4,740,000

'

'

'

'

'

'

384,000

347,000

358,000

364,000

382,000

434,000

330,000

136,000

76,000

332,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

$15.82

$14.06

$13.36

$12.86

'

'

'

'

'

'

$10.65

$12.84

$13.86

$14.58

$16.79

$19.84

$22.52

$24.61

$29.16

$8.71

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

2,078,000

'

'

'

'

'

'

'

'

'

384,000

291,000

143,000

167,000

106,000

369,000

104,000

106,000

76,000

332,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price

$15.11

'

'

'

'

'

'

'

'

'

$10.65

$12.77

$13.94

$14.67

$16.51

$20.12

$21.50

$24.76

$29.16

$8.71

Number of shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

'

'

'

'

58,000

68,000

77,000

389,000

287,000

308,000

'

'

'

'

'

'

'

'

'

'

Granted

'

'

'

'

55,000

67,000

68,000

190,000

274,000

145,000

'

'

'

'

'

'

'

'

'

'

Vested

'

'

'

'

-61,000

-78,000

-77,000

-195,000

-153,000

-152,000

'

'

'

'

'

'

'

'

'

'

Forfeited

'

'

'

'

'

'

'

22,000

-19,000

-14,000

'

'

'

'

'

'

'

'

'

'

Ending balance

'

'

'

'

52,000

58,000

68,000

362,000

389,000

287,000

'

'

'

'

'

'

'

'

'

'

Weighted-average grant date fair value per share [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

'

'

'

'

$14.19

$14.71

$12.91

$14.09

$13.03

$12.98

'

'

'

'

'

'

'

'

'

'

Granted

'

'

'

'

$18.20

$14.19

$14.71

$19.87

$14.58

$14.39

'

'

'

'

'

'

'

'

'

'

Vested

'

'

'

'

$14.23

$14.64

$12.91

$14.31

$12.90

$14.26

'

'

'

'

'

'

'

'

'

'

Forfeited

'

'

'

'

'

'

'

$14.08

$14.55

$12.82

'

'

'

'

'

'

'

'

'

'

Ending balance

'

'

'

'

$18.43

$14.19

$14.71

$17.15

$14.09

$13.03

'

'

'

'

'

'

'

'

'

'

Vested in period, fair value

'

'

'

'

$1,126,670

$1,100,000

$1,100,000

$4,400,000

$2,300,000

$2,400,000

'

'

'

'

'

'

'

'

'

'

Compensation cost not yet recognized

'

'

'

'

$400,000

'

'

$5,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Period for recognition

'

'

'

'

'2 years

'

'

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa7

Stock Option Plans and Share-Based Compensation PSU performance to vesting table by Program year (Details) (USD $)

12 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Jan. 22, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 17, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Vested Performance Shares [Domain]

Below the 35th percentile ranking [Member]

Below 50th percentile ranking [Member]

At least 50th percentile (after yr one) [Member]

2012 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

2011 PSU [Member]

PSU program year one [Member]

PSU Program Year Two [Member]

PSU Program Year Two [Member]

PSU Program Year Two [Member]

Below the 35th percentile ranking [Member]

Below 50th percentile ranking [Member]

Below the 65th percentile ranking [Member]

At the 70th percentile ranking [Member]

Below the 75th percentile ranking [Member]

At or above the 75th percentile ranking [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted

'

'

'

142,000

135,000

100,000

'

'

'

'

'

'

125,000

'

'

'

'

'

'

'

'

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

'

'

'

'

'

'

'

120,000

'

'

'

'

'

'

'

30,000

Number of shares eligible for vesting

'

'

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

share-based compensation arrangement by share-based payment award, number of shares vested for the period

'

'

'

31,244

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

-57,000

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation cost not yet recognized

'

'

'

$1,125,413

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for recognition

'

'

'

'1 year 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

$11,151,000

$9,214,000

$9,499,000

'

$1,000,000

$600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trading days considered in shareholder return calc

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

'

'

0.00%

50.00%

100.00%

'

'

'

'

'

'

0.00%

50.00%

100.00%

115.00%

110.00%

120.00%

'

Percentile ranking of shareholder return

'

'

'

'

'

'

'

'

'

35.30%

'

'

'

76.30%

'

'

'

'

'

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

120.00%

'

'

'

'

'

'

'

'

Share vesting rate

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

'

'

25.00%

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa8

Stock Option Plans and Share-Based Compensation Performance based stock units (PSU) (Details) (Performance Shares [Member], USD $)	12 Months Ended			9 Months Ended	12 Months Ended		0 Months Ended	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Mar. 05, 2013	Sep. 30, 2013
				2012 PSU [Member]	2012 PSU [Member]	2012 PSU [Member]	2013 PSU [Member]	2013 PSU [Member]
Number of units [Roll Forward]	'	'	'	'	'	'	'	'
Beginning balance	175,000	100,000	'	'	'	'	'	'
Granted	142,000	135,000	100,000	'	'	125,000	12,500	125,000
Share-based Compensation Arrangement by Share-based Payment Award, First Year Share Vesting Rate	'	'	'	25.00%	25.00%	'	'	'
Vested	57,000	-60,000	'	'	'	'	'	'
Forfeited	35,000	0	'	'	'	'	'	'
Ending balance	225,000	175,000	100,000	'	'	'	'	'
Weighted-average grant date fair value per unit [Roll Forward]	'	'	'	'	'	'	'	'
Beginning balance	$11	$11.15	'	'	'	'	'	'
Granted	$14.68	$10.94	'	'	'	'	'	'
Vested	$11.15	$11.15	'	'	'	'	'	'
Forfeited	$10.93	$0	'	'	'	'	'	'
Ending balance	$13.32	$11	$11.15	'	'	'	'	'

Segments_Details

Segments (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Revenues	$380,585,000	$314,027,000	$245,535,000
Cost of Revenue	177,186,000	143,439,000	109,751,000
Gross profit	203,399,000	170,588,000	135,784,000
Gross Margin Percentage	53.40%	54.30%	55.30%
Operating Expenses	168,100,000	143,462,000	119,562,000
Income from operations	35,299,000	27,126,000	16,222,000
Operating margin percentage	9.30%	8.60%	6.60%
Interest and other income (expense), net	-270,000	-51,000	-133,000
Income before provision for income taxes	35,029,000	27,075,000	16,089,000
Provision for income taxes	11,050,000	10,897,000	5,700,000
Net income	23,979,000	16,178,000	10,389,000
Assets	492,501,000	441,819,000	'
Depreciation and amortization	18,365,000	13,325,000	7,983,000
Property, Plant and Equipment, Additions	12,335,000	15,187,000	'
Acute Care Solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Operating Expenses Acquisition Expenses	'	2,300,000	'
Revenues	284,666,000	260,160,000	245,535,000
Cost of Revenue	122,816,000	111,599,000	109,751,000
Gross profit	161,850,000	148,561,000	135,784,000
Gross Margin Percentage	56.90%	57.10%	55.30%
Operating Expenses	131,811,000	127,467,000	119,562,000
Income from operations	30,039,000	21,094,000	16,222,000
Operating margin percentage	10.60%	8.10%	6.60%
Assets	263,154,000	235,186,000	363,849,000
Depreciation and amortization	11,236,000	9,017,000	7,983,000
Property, Plant and Equipment, Additions	4,392,000	13,234,000	8,685,000
Non-acute care solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Operating Expenses Acquisition Expenses	'	900,000	'
Cost of Revenues Acquisition Charges	'	1,700,000	'
Revenues	95,919,000	53,867,000	'
Cost of Revenue	54,370,000	31,840,000	'
Gross profit	41,549,000	22,027,000	'
Gross Margin Percentage	43.30%	40.90%	'
Operating Expenses	36,289,000	15,995,000	'
Income from operations	5,260,000	6,032,000	'
Operating margin percentage	5.50%	11.20%	'
Assets	229,347,000	206,633,000	'
Depreciation and amortization	7,129,000	4,308,000	'
Property, Plant and Equipment, Additions	7,943,000	1,953,000	'
MTS-Medication Technologies [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	'	47,200,000	'
MTS-Medication Technologies [Member] | Non-acute care solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net income	'	2,900,000	'
COS relief of FV inventory step-up and misc [Member] | MTS-Medication Technologies [Member] | Non-acute care solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Cost of Revenue	'	1,700,000	'
Acq trransaction costs [Member] | MTS-Medication Technologies [Member] | Acute Care Solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Operating Expenses	'	2,300,000	'
Severance and misc cost [Member] | MTS-Medication Technologies [Member] | Non-acute care solutions [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Operating Expenses	'	$900,000	'

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Line of Credit Facility, Maximum Borrowing Capacity	$75
Letter of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	10
Potential Increase in Aggregate Commitments [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$25
Eurodollar Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%
Federal Funds Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	0.50%
LIBOR [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%

Asset_Impairment_Details

Asset Impairment (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2013
Asset Impairment [Abstract]	'
Asset Impairment Charges	$1,759
Change in accounting estimate impact on dilted eps	$0.03

Schedule_II_Details

Schedule II (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Valuation Allowances and Reserves, Beginning Balance	$1,329	$727	$908
Valuation Allowances and Reserves, Charged to Cost and Expense	244	741	63
Valuation Allowances and Reserves, Period Increase (Decrease)	-67	-57	-118
Valuation Allowances and Reserves, Deductions	849	82	126
Valuation Allowances and Reserves, Ending Balance	657	1,329	727
Allowance for Trade Receivables [Member]	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Valuation Allowances and Reserves, Beginning Balance	722	443	497
Valuation Allowances and Reserves, Charged to Cost and Expense	195	316	63
Valuation Allowances and Reserves, Period Increase (Decrease)	-67	-57	-96
Valuation Allowances and Reserves, Deductions	360	-20	21
Valuation Allowances and Reserves, Ending Balance	490	722	443
Allowance for Loan and Lease Losses [Member]	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Valuation Allowances and Reserves, Beginning Balance	607	284	411
Valuation Allowances and Reserves, Charged to Cost and Expense	49	425	0
Valuation Allowances and Reserves, Period Increase (Decrease)	0	0	-22
Valuation Allowances and Reserves, Deductions	489	102	105
Valuation Allowances and Reserves, Ending Balance	$167	$607	$284